QUARTERLY REPORT

Q1 FY2020 — Quarterly report (Form 10-Q)

Q1 FY2020PDF · 45 pages421 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 	10-Q
(Mark one)
x 	True 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended 	September 30, 2019
OR
o 	False 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from 	to
PROCTER & GAMBLE COMPANY
(Exact name of registrant as specified in its charter)
Ohio 	OH 	1-434 	31-0411980
(State of Incorporation) 	(Commission File Number) 	(I.R.S. Employer Identification Number)
One Procter & Gamble Plaza	
Cincinnati 	OH
One Procter & Gamble Plaza, Cincinnati, Ohio 	45202
(Address of principal executive offices) 	(Zip Code)
(513) 	983-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol 	Name of each exchange on which registered
Common Stock, without Par Value 	PG 	NYSE
4.125% EUR notes due December 2020 	PG20A 	NYSE
0.275% Notes due 2020 	PG20 	NYSE
2.000% Notes due 2021 	PG21 	NYSE
2.000% Notes due 2022 	PG22B 	NYSE
1.125% Notes due 2023 	PG23A 	NYSE
0.500% Notes due 2024 	PG24A 	NYSE
0.625% Notes due 2024 	PG24B 	NYSE
1.375% Notes due 2025 	PG25 	NYSE
4.875% EUR notes due May 2027 	PG27A 	NYSE
1.200% Notes due 2028 	PG28 	NYSE
1.250% Notes due 2029 	PG29B 	NYSE
1.800% Notes due 2029 	PG29A 	NYSE
6.250% GBP notes due January 2030 	PG30 	NYSE
5.250% GBP notes due January 2033 	PG33 	NYSE
1.875% Notes due 2038 	PG38 	NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes 	þ 	No 	o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit such files).
Yes 	þ 	No 	o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer,"
"accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act).
Large accelerated filer 	þ 	Accelerated filer 	¨
Non-accelerated filer 	¨ 	Smaller reporting company 	¨ 	False
Emerging growth company 	¨ 	False
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of
the Exchange Act. 	¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes 	o 	No 	þ 	False
There were 	2,493,812,048 	shares of Common Stock outstanding as of September 30, 2019.

-- 1 of 45 --

PART I. FINANCIAL INFORMATION
Item 1. 	Financial Statements
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
Three Months Ended September 30
Amounts in millions except per share amounts 	2019 	2018
NET SALES 	$ 	17,798 	$ 	16,690
Cost of products sold 	8,723 	8,484
Selling, general and administrative expense 	4,785 	4,652
OPERATING INCOME 	4,290 	3,554
Interest expense 	(108) 	(129)
Interest income 	58 	53
Other non-operating income, net 	103 	462
EARNINGS BEFORE INCOME TAXES 	4,343 	3,940
Income taxes 	726 	729
NET EARNINGS 	3,617 	3,211
Less: Net earnings attributable to noncontrolling interests 	24 	12
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	3,593 	$ 	3,199
NET EARNINGS PER SHARE 	(1)
Basic 	$ 	1.41 	$ 	1.26
Diluted 	$ 	1.36 	$ 	1.22
DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING 	2,647.5 	2,612.1
(1) 	Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
See accompanying Notes to Consolidated Financial Statements.

-- 2 of 45 --

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)
Three Months Ended
September 30
Amounts in millions 	2019 	2018
NET EARNINGS 	$ 	3,617 	$ 	3,211
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation 	(540) 	(209)
Unrealized gains/(losses) on investment securities 	(5) 	(5)
Unrealized gains/(losses) on defined benefit retirement plans 	179 	152
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX 	(366) 	(62)
TOTAL COMPREHENSIVE INCOME 	3,251 	3,149
Less: Total comprehensive income attributable to noncontrolling interests 	20 	8
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	3,231 	$ 	3,141
See accompanying Notes to Consolidated Financial Statements.

-- 3 of 45 --

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
Amounts in millions 	September 30, 2019 	June 30, 2019
Assets
CURRENT ASSETS
Cash and cash equivalents 	$ 	9,304 	$ 	4,239
Available-for-sale investment securities 	— 	6,048
Accounts receivable 	5,143 	4,951
INVENTORIES
Materials and supplies 	1,394 	1,289
Work in process 	656 	612
Finished goods 	3,415 	3,116
Total inventories 	5,465 	5,017
Prepaid expenses and other current assets 	2,013 	2,218
TOTAL CURRENT ASSETS 	21,925 	22,473
PROPERTY, PLANT AND EQUIPMENT, NET 	20,901 	21,271
GOODWILL 	39,605 	40,273
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 	24,002 	24,215
OTHER NONCURRENT ASSETS 	7,625 	6,863
TOTAL ASSETS 	$ 	114,058 	$ 	115,095
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable 	$ 	10,951 	$ 	11,260
Accrued and other liabilities 	9,950 	9,054
Debt due within one year 	9,352 	9,697
TOTAL CURRENT LIABILITIES 	30,253 	30,011
LONG-TERM DEBT 	20,161 	20,395
DEFERRED INCOME TAXES 	6,325 	6,899
OTHER NONCURRENT LIABILITIES 	10,335 	10,211
TOTAL LIABILITIES 	67,074 	67,516
SHAREHOLDERS’ EQUITY
Preferred stock 	915 	928
Common stock – shares issued – 	September 2019 	4,009.2
June 2019 	4,009.2 	4,009 	4,009
Additional paid-in capital 	63,949 	63,827
Reserve for ESOP debt retirement 	(1,112) 	(1,146)
Accumulated other comprehensive income/(loss) 	(15,298) 	(14,936)
Treasury stock 	(102,510) 	(100,406)
Retained earnings 	96,625 	94,918
Noncontrolling interest 	406 	385
TOTAL SHAREHOLDERS’ EQUITY 	46,984 	47,579
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 	$ 	114,058 	$ 	115,095
See accompanying Notes to Consolidated Financial Statements.

-- 4 of 45 --

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
Three Months Ended September 30, 2019
Dollars in millions; shares in
thousands
Common Stock
Preferred
Stock
Add-itional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumu-lated
Other
Comp-rehensive
Income/(Loss) 	Treasury Stock
Retained
Earnings
Non-
controlling
Interest
Total Share-
holders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2019 	2,504,751 	$4,009 	$928 	$63,827 	($1,146) 	($14,936) 	($100,406) 	$94,918 	$385 	$47,579
Net earnings 	3,593 	24 	3,617
Other comprehensive income/(loss) 	(362) 	(4) 	(366)
Dividends and dividend equivalents
($0.7459 per share):
Common 	(1,874) 	(1,874)
Preferred, net of tax benefits 	(65) 	(65)
Treasury stock purchases 	(25,405) 	(3,000) 	(3,000)
Employee stock plans 	13,050 	120 	885 	1,005
Preferred stock conversions 	1,416 	(13) 	2 	11 	—
ESOP debt impacts 	34 	53 	87
Noncontrolling interest, net 	1 	1
BALANCE
SEPTEMBER 30, 2019 	2,493,812 	$4,009 	$915 	$63,949 	($1,112) 	($15,298) 	($102,510) 	$96,625 	$406 	$46,984
Three Months Ended September 30, 2018
Dollars in millions; shares in
thousands
Common Stock
Preferred
Stock
Add-itional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumu-lated
Other
Comp-rehensive
Income/(Loss)
Treasury
Stock
Retained
Earnings
Non-
controlling
Interest
Total Share-
holders'
Equity	Shares 	Amount
BALANCE
JUNE 30, 2018 	2,498,093 	$4,009 	$967 	$63,846 	($1,204) 	($14,749) 	($99,217) 	$98,641 	$590 	$52,883
Impact of adoption of new
accounting standards 	(326) 	(200) 	(27) 	(553)
Net earnings 	3,199 	12 	3,211
Other comprehensive
income/(loss) 	(58) 	(4) 	(62)
Dividends and dividend
equivalents
($0.7172 per share):
Common 	(1,791) 	(1,791)
Preferred, net of tax benefits 	(66) 	(66)
Treasury stock purchases 	(15,690) 	(1,252) 	(1,252)
Employee stock plans 	7,368 	20 	500 	520
Preferred stock conversions 	1,637 	(16) 	3 	13 	—
ESOP debt impacts 	27 	48 	75
Noncontrolling interest, net 	(158) 	(303) 	(461)
BALANCE
SEPTEMBER 30, 2018 	2,491,408 	$4,009 	$951 	$63,711 	($1,177) 	($15,133) 	($99,956) 	$99,831 	$268 	$52,504
See accompanying Notes to Consolidated Financial Statements.

-- 5 of 45 --

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended September
30
Amounts in millions 	2019 	2018
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD 	$ 	4,239 	$ 	2,569
OPERATING ACTIVITIES
Net earnings 	3,617 	3,211
Depreciation and amortization 	723 	643
Share-based compensation expense 	110 	102
Deferred income taxes 	(586) 	34
Gain on sale of assets 	(2) 	(361)
Changes in:
Accounts receivable 	(261) 	(475)
Inventories 	(549) 	(494)
Accounts payable, accrued and other liabilities 	1,151 	933
Other operating assets and liabilities 	(35) 	(84)
Other 	1 	58
TOTAL OPERATING ACTIVITIES 	4,169 	3,567
INVESTING ACTIVITIES
Capital expenditures 	(1,079) 	(1,080)
Proceeds from asset sales 	6 	9
Acquisitions, net of cash acquired 	— 	(237)
Purchases of short-term investments 	— 	(158)
Proceeds from sales and maturities of investment securities 	6,151 	649
Change in other investments 	1 	(48)
TOTAL INVESTING ACTIVITIES 	5,079 	(865)
FINANCING ACTIVITIES
Dividends to shareholders 	(1,932) 	(1,853)
Change in short-term debt 	(61) 	24
Treasury stock purchases 	(3,000) 	(1,252)
Impact of stock options and other 	875 	425
TOTAL FINANCING ACTIVITIES 	(4,118) 	(2,656)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	(65) 	(70)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	5,065 	(24)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD 	$ 	9,304 	$ 	2,545
See accompanying Notes to Consolidated Financial Statements.

-- 6 of 45 --

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
These statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended 	June 30, 2019. In the opinion of
management, the accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries (the "Company," "Procter &
Gamble," "P&G," "we" or "our") contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim
periods reported. However, the results of operations included in such financial statements may not necessarily be indicative of annual results.
2. New Accounting Pronouncements and Policies
On July 1, 2019, we adopted ASU 2016-02, "Leases (Topic 842)." The new accounting standard required the recognition of right-of-use assets and lease liabilities
for all long-term leases, including operating leases, on the balance sheet. We elected the optional transition method and adopted the new guidance on a modified
retrospective basis with no restatement of prior period amounts. As allowed under the new accounting standard, we elected to apply practical expedients to carry
forward the original lease determinations, lease classifications and accounting of initial direct costs for all asset classes at the time of adoption. The adoption did
not have a material impact on our financial statements, resulting in an increase of approximately 	1% 	to each of our total assets and total liabilities on our balance
sheet as of July 1, 2019. See Note 10 for further information.
In January 2017, the FASB issued ASU 2017-04, "Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment." The standard
simplifies the accounting for goodwill impairment by requiring a goodwill impairment to be measured using a single step impairment model, whereby the
impairment equals the difference between the carrying amount and the fair value of the specified reporting units in their entirety. This eliminates the second step of
the current impairment model that requires companies to first estimate the fair value of all assets in a reporting unit and measure impairments based on those fair
values and a residual measurement approach. It also specifies that any loss recognized should not exceed the total amount of goodwill allocated to that reporting
unit. We will adopt the standard no later than July 1, 2020. The impact of the new standard will be dependent on the specific facts and circumstances of future
individual impairments, if any.
No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial
Statements.
3. Segment Information
Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and 5)
Baby, Feminine & Family Care. Our five reportable segments are comprised of:
• 	Beauty: Hair Care (Conditioner, Shampoo, Styling Aids, Treatments); Skin and Personal Care (Antiperspirant and Deodorant, Personal Cleansing, Skin Care);
• 	Grooming: Shave Care (Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Shave Care); Appliances
• 	Health 	Care: 	Oral 	Care 	(Toothbrushes, 	Toothpaste, 	Other 	Oral 	Care); 	Personal 	Health 	Care 	(Gastrointestinal, 	Rapid 	Diagnostics, 	Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health Care);
• 	Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional, Surface
Care); and
• 	Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Feminine Care); Family Care (Paper
Towels, Tissues, Toilet Paper).
Amounts in millions of dollars unless otherwise specified.

-- 7 of 45 --

Our operating segments are comprised of similar product categories. Operating segments that individually accounted for 5% or more of consolidated net sales are
as follows:
% of Net sales by operating segment 	(1)
Three Months Ended September 30
2019 	2018
Fabric Care 	23% 	23%
Baby Care 	11% 	12%
Home Care 	10% 	10%
Hair Care 	10% 	10%
Skin and Personal Care 	10% 	9%
Family Care 	9% 	9%
Oral Care 	7% 	8%
Shave Care 	7% 	8%
Feminine Care 	6% 	6%
Personal Health Care 	5% 	3%
Other 	2% 	2%
Total 	100% 	100%
(1) 	% of Net sales by operating segment excludes sales held in Corporate.
Following is a summary of reportable segment results:
Three Months Ended September 30
Net Sales
Earnings/(Loss)
Before Income Taxes 	Net Earnings
Beauty 	2019 	$ 	3,552 	$ 	1,092 	$ 	874
2018 	3,289 	947 	759
Grooming 	2019 	1,531 	426 	353
2018 	1,562 	417 	340
Health Care 	2019 	2,221 	540 	401
2018 	1,845 	440 	332
Fabric & Home Care 	2019 	5,832 	1,338 	1,028
2018 	5,488 	1,144 	877
Baby, Feminine & Family Care 	2019 	4,567 	1,134 	871
2018 	4,390 	902 	692
Corporate 	2019 	95 	(187) 	90
2018 	116 	90 	211
Total Company 	2019 	$ 	17,798 	$ 	4,343 	$ 	3,617
2018 	16,690 	3,940 	3,211
Amounts in millions of dollars unless otherwise specified.

-- 8 of 45 --

4. Goodwill and Other Intangible Assets
Goodwill is allocated by reportable segment as follows:
Beauty 	Grooming 	Health Care
Fabric & Home
Care
Baby, Feminine &
Family Care 	Total Company
Goodwill at June 30, 2019 	$ 	12,985 	$ 	12,881 	$ 	7,972 	$ 	1,855 	$ 	4,580 	$ 	40,273
Acquisitions and divestitures 	(1) 	— 	(53) 	— 	— 	(54)
Translation and other 	(222) 	(159) 	(153) 	(18) 	(62) 	(614)
Goodwill at September 30, 2019 	$ 	12,762 	$ 	12,722 	$ 	7,766 	$ 	1,837 	$ 	4,518 	$ 	39,605
Goodwill from current year acquisitions and divestitures primarily reflects opening balance sheet adjustments from the prior year acquisition of the over-the-
counter (OTC) healthcare business of Merck KGaA (Merck OTC) in the Health Care reportable segment (see Note 12), along with adjustments from a prior year
Beauty acquisition.
Identifiable intangible assets at 	September 30, 2019 	were comprised of:
Gross Carrying Amount 	Accumulated Amortization
Intangible assets with determinable lives 	$ 	8,452 	$ 	(5,443)
Intangible assets with indefinite lives 	20,993 	—
Total identifiable intangible assets 	$ 	29,445 	$ 	(5,443)
Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives consist of
brands. The amortization expense of determinable lived intangible assets for the three months ended 	September 30, 2019 	and 	2018 	was 	$96 	and 	$73, respectively.
Goodwill and indefinite lived intangible assets are not amortized, but are tested annually for impairment. The test to evaluate goodwill for impairment is a two-step
process. In the first step, we compare the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit is less than its carrying value, we
perform a second step (the step two testing) to determine the implied fair value of the reporting unit's goodwill. The step two testing of the impairment analysis
requires a valuation of a reporting unit's tangible and intangible assets and liabilities in a manner similar to the allocation of purchase price in a business
combination. If the resulting implied fair value of the reporting unit's goodwill is less than its carrying value, that difference represents an impairment.
The business unit valuations used to test goodwill and intangible assets for impairment are dependent on a number of significant estimates and assumptions,
including macroeconomic conditions, overall category growth rates, competitive activities, cost containment, margin expansion and Company business plans. We
believe these estimates and assumptions are reasonable. However, future changes in the judgments, assumptions and estimates that are used in our impairment
testing for goodwill and indefinite-lived intangible assets, including discount and tax rates or future cash flow projections, could result in significantly different
estimates of the fair values. Our annual impairment testing for goodwill and indefinite lived intangible assets occurs during the three months ended December 31.
Most of our goodwill reporting units are comprised of a combination of legacy and acquired businesses and as a result have fair value cushions that, at a minimum,
exceed two times their underlying carrying values. Certain of our goodwill reporting units, in particular Shave Care and Appliances, are comprised entirely of
acquired businesses and as a result, have fair value cushions that are not as high. The Appliances wholly-acquired reporting unit has a fair value that significantly
exceeds the underlying carrying value. As previously disclosed, the carrying value of the Shave Care reporting unit and the related Gillette indefinite-lived
intangible asset were impaired during the year ended June 30, 2019. 	The underlying reductions in fair values were due in large part to significant currency
devaluations in a number of countries relative to the U.S. dollar, a deceleration of category growth caused by changing grooming habits, primarily in the developed
markets, and an increased competitive market environment in the U.S. and certain other markets. As a result of the impairment determined by the step two testing,
the Shave Care fair value exceeded the carrying value by approximately 	20% 	as of June 30, 2019. Because the impairment testing for intangible assets is a one step
process, the Gillette indefinite-lived intangible asset fair value approximated its carrying value at that date. As a result, the Gillette indefinite-lived intangible asset
is more susceptible to future impairment risk.
Amounts in millions of dollars unless otherwise specified.

-- 9 of 45 --

The most significant assumptions utilized in the determination of the estimated fair values of Shave Care reporting unit and the Gillette indefinite-lived intangible
asset are the net sales and earnings growth rates (including residual growth rates) and discount rate. The residual growth rate represents the expected rate at which
the reporting unit and Gillette brand are expected to grow beyond the shorter-term business planning period. The residual growth rate utilized in our fair value
estimates is consistent with the reporting unit and brand operating plans, and approximates expected long term category market growth rates. The residual growth
rate is dependent on overall market growth rates, the competitive environment, inflation, relative currency exchange rates and business activities that impact market
share. As a result, the residual growth rate could be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of
currencies against the U.S. dollar or an increased competitive environment. The discount rate, which is consistent with a weighted average cost of capital that is
likely to be expected by a market participant, is based upon industry required rates of return, including consideration of both debt and equity components of the
capital structure. Our discount rate may be impacted by adverse changes in the macroeconomic environment, volatility in the equity and debt markets or other
country specific factors, such as further devaluation of currencies against the U.S. dollar. Based on developments in the macroeconomic environment during the
quarter ended September 30, 2019, the discount rate utilized in our annual impairment testing for goodwill and indefinite lived intangible assets during the three
months ended December 31 will likely decline, resulting in an increase in the implied fair value estimates. Spot rates as of the fair value measurement date are
utilized in our fair value estimates for cash flows outside the U.S.
While management can and has implemented strategies to address these events, changes in operating plans or adverse changes in the business or in the
macroeconomic environment in the future could reduce the underlying cash flows used to estimate fair values and could result in a decline in fair value that would
trigger future impairment charges of the reporting unit's goodwill and indefinite-lived intangibles. As of 	September 30, 2019, the carrying values of the Shave Care
goodwill and the Gillette indefinite-lived intangible asset were 	$12.4 billion 	and 	$14.1 billion, respectively.
The table below provides a sensitivity analysis for the Shave Care reporting unit and the Gillette indefinite lived intangible asset, utilizing reasonably possible
changes in the assumptions for the shorter term and residual growth rates and the discount rate, to demonstrate the potential impacts to the estimated fair values.
The table below provides, in isolation, the estimated fair value impacts related to a 25 basis point increase to discount rate or a 25 basis point decrease to our
shorter-term and residual growth rates.
Approximate Percent Change in Estimated Fair Value
+25 bps Discount Rate 	-25 bps Growth Rate
Shave Care goodwill reporting unit 	(5)% 	(6)%
Gillette indefinite-lived intangible asset 	(5)% 	(5)%
Amounts in millions of dollars unless otherwise specified.

-- 10 of 45 --

5. Earnings Per Share
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted average
number of common shares outstanding during the period. Diluted net earnings per common share are calculated using the treasury stock method, on the basis of the
weighted average number of common shares outstanding plus the dilutive effect of stock options and other stock-based awards and the assumed conversion of
preferred stock.
Net earnings per share were as follows:
CONSOLIDATED AMOUNTS Three Months Ended
September 30
2019 	2018
Net earnings 	$ 	3,617 	$ 	3,211
Less: Net earnings attributable to noncontrolling interests 	24 	12
Net earnings attributable to P&G (Diluted) 	3,593 	3,199
Preferred dividends 	(65) 	(66)
Net earnings attributable to P&G available to common shareholders (Basic) 	$ 	3,528 	$ 	3,133
SHARES IN MILLIONS
Basic weighted average common shares outstanding 	2,504.0 	2,495.8
Add: Effect of dilutive securities
Conversion of preferred shares 	(1) 	87.4 	91.9
Impact of stock options and other unvested equity awards 	(2) 	56.1 	24.4
Diluted weighted average common shares outstanding 	2,647.5 	2,612.1
NET EARNINGS PER SHARE 	(3)
Basic 	$ 	1.41 	$ 	1.26
Diluted 	$ 	1.36 	$ 	1.22
(1) 	Despite being included currently in Diluted net earnings per common share, the actual conversion to common stock occurs when the preferred shares are sold.
Shares may only be sold after being allocated to the ESOP participants pursuant to the repayment of the ESOP's obligations through 2035.
(2) 	Weighted average outstanding stock options of approximately 	1 million 	and 	69 million 	for the three months ended 	September 30, 2019 	and 	2018 	were not
included in the Diluted net earnings per share calculation because the options were out of the money or to do so would have been antidilutive (i.e., the total
proceeds upon exercise would have exceeded the market value of the underlying common shares).
(3) 	Net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
6. Share-Based Compensation and Postretirement Benefits
The following table provides a summary of our share-based compensation expense and postretirement benefit costs:
Three Months Ended September
30
2019 	2018
Share-based compensation expense 	$ 	110 	$ 	102
Net periodic benefit cost for pension benefits 	(1) 	40 	28
Net periodic benefit cost/(credit) for other retiree benefits 	(1) 	(52) 	(41)
(1) 	The components of the total net periodic benefit cost for both pension benefits and other retiree benefits for these interim periods, on an annualized basis, do
not differ materially from the amounts disclosed in the Annual Report on Form 10-K for the fiscal year ended 	June 30, 2019.
Amounts in millions of dollars unless otherwise specified.

-- 11 of 45 --

7. Risk Management Activities and Fair Value Measurements
As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and
commodity prices. There have been no significant changes in our risk management policies or activities during the 	three 	months ended 	September 30, 2019.
The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company
recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods
presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. There were no significant assets or liabilities
that were remeasured at fair value on a non-recurring basis for the 	three 	months ended 	September 30, 2019.
Other investments had a fair value of 	$62 	and 	$169 	as of 	September 30, 2019 	and 	June 30, 2019, respectively, and are presented in Other noncurrent assets. During
the 	three 	months ended 	September 30, 2019, the Company sold all of its existing U.S. government securities and corporate bond securities. Such securities were
presented in Available-for-sale investment securities at 	June 30, 2019, and had fair values of 	$3,648 	and 	$2,400, respectively. The Company's investments
measured at fair value are generally classified as Level 2 within the fair value hierarchy. Cash equivalents were 	$7,955 	and 	$2,956 	as of 	September 30, 2019 	and
June 30, 2019, respectively, and are classified as Level 1 within the fair value hierarchy. There are no other material investment balances classified as Level 1 or
Level 3 within the fair value hierarchy, or using net asset value as a practical expedient. Fair values are generally estimated based upon quoted market prices for
similar instruments.
The fair value of long-term debt was 	$25,196 	and 	$25,378 	as of 	September 30, 2019 	and 	June 30, 2019, respectively. This includes the current portion of debt
instruments ($3,291 	and 	$3,390 	as of 	September 30, 2019 	and 	June 30, 2019, respectively). Certain long-term debt (debt designated as a fair value hedge) is
recorded at fair value. All other long-term debt is recorded at amortized cost, but is measured at fair value for disclosure purposes. We consider our debt to be
Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar instruments.
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of 	September 30, 2019 	and 	June 30, 2019 	are as follows:
Notional Amount 	Fair Value Asset 	Fair Value (Liability)
September 30, 2019 	June 30, 2019 	September 30, 2019 	June 30, 2019 	September 30, 2019 	June 30, 2019
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	7,524 	$ 	7,721 	$ 	266 	$ 	177 	$ 	— 	$ 	(1)
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	3,309 	$ 	3,157 	$ 	104 	$ 	35 	$ 	(16) 	$ 	(24)
TOTAL DERIVATIVES DESIGNATED AS
HEDGING INSTRUMENTS 	$ 	10,833 	$ 	10,878 	$ 	370 	$ 	212 	$ 	(16) 	$ 	(25)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	6,196 	$ 	6,431 	$ 	19 	$ 	27 	$ 	(49) 	$ 	(20)
TOTAL DERIVATIVES AT FAIR VALUE 	$ 	17,029 	$ 	17,309 	$ 	389 	$ 	239 	$ 	(65) 	$ 	(45)
All derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. All derivative liabilities are presented in Accrued and
other liabilities or Other noncurrent liabilities.
The fair value of the interest rate derivative asset/liability directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying
amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the fair
value adjustment, was 	$7,756 	and 	$7,860 	as of 	September 30, 2019 	and 	June 30, 2019, respectively. In addition to the foreign currency derivative contracts
designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The carrying value of
those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on those instruments,
was 	$16,995 	and 	$17,154 	as of 	September 30, 2019 	and 	June 30, 2019, respectively. Changes in the fair value of net investment hedges are recognized in the
Foreign Currency Translation component of Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are
classified as Level 2 within the fair value hierarchy.
Amounts in millions of dollars unless otherwise specified.

-- 12 of 45 --

Before tax gains/(losses) on our financial instruments in hedging relationships are categorized as follows:
Amount of Gain/(Loss) Recognized in OCI on Derivatives
Three Months Ended September 30
2019 	2018
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS 	(1) (2)
Foreign exchange contracts 	$ 	113 	$ 	(43)
(1) 	For the derivatives in net investment hedging relationships, the amount of gain/(loss) excluded from effectiveness testing, which was recognized in earnings,
was 	$19 	and 	$14 	for the 	three 	months ended 	September 30, 2019 	and 	2018, respectively.
(2) 	In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are
designated as net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income/(loss) (AOCI) for such instruments
was 	$609 	and 	$207, for the 	three 	months ended 	September 30, 2019 	and 	2018, respectively.
Amount of Gain/(Loss) Recognized in Earnings
Three Months Ended September 30
2019 	2018
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	90 	$ 	(24)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	(97) 	$ 	(2)
The gain/(loss) on the derivatives in fair value hedging relationships is fully offset by the mark-to-market impact of the related exposure. These are both recognized
in the Consolidated Statements of Earnings in Interest expense. The gain/(loss) on derivatives not designated as hedging instruments is substantially offset by the
currency mark-to-market of the related exposure. These are both recognized in the Consolidated Statements of Earnings in Selling, general and administrative
expense (SG&A).
8. Accumulated Other Comprehensive Income/(Loss)
The table below presents the changes in AOCI, including the reclassifications out of AOCI by component:
Investment Securities
Pension and Other
Retiree Benefits
Foreign Currency
Translation 	Total AOCI
Balance at June 30, 2019 	$ 	11 	$ 	(4,198) 	$ 	(10,749) 	$ 	(14,936)
OCI before reclassifications 	(1) 	(3) 	104 	(540) 	(439)
Amounts reclassified from AOCI into the Consolidated Statements of Earnings 	(2) 	(2) 	75 	— 	73
Net current period OCI 	(5) 	179 	(540) 	(366)
Less: Other comprehensive income/(loss) attributable to non-controlling interests 	— 	— 	(4) 	(4)
Balance at September 30, 2019 	$ 	6 	$ 	(4,019) 	$ 	(11,285) 	$ 	(15,298)
(1) 	Net of tax expense/(benefit) of 	$0, 	$51 	and 	$170 	for gains/losses on investment securities, pension and other retiree benefit items and foreign currency
translation, respectively.
(2) 	Net of tax expense/(benefit) of 	$0, 	$20 	and 	$0 	for gains/losses on investment securities, pension and other retiree benefit items and foreign currency
translation, respectively.
The below provides additional details on amounts reclassified from AOCI into the Consolidated Statements of Earnings:
• 	Investment securities: amounts reclassified from AOCI into Other non-operating income, net.
• 	Pension and other retiree benefits: amounts reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic
postretirement costs.
Amounts in millions of dollars unless otherwise specified.

-- 13 of 45 --

9. Restructuring Program
The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including manufacturing
and workforce optimization. Before-tax costs incurred under the ongoing program have generally ranged from 	$250 	to 	$500 	annually.
In fiscal 2017 the Company announced specific elements of a multi-year productivity and cost savings plan to further reduce costs in the areas of supply chain,
certain marketing activities and overhead expenses. This program is expected to result in incremental enrollment reductions, along with further optimization of the
supply chain and other manufacturing processes.
Restructuring costs incurred consist primarily of costs to separate employees, asset-related costs to exit facilities and other costs. For the 	three 	month period ended
September 30, 2019, the Company incurred total restructuring charges of 	$93. Approximately 	$70 	of these charges were recorded in Cost of products sold and
approximately 	$22 	of these charges were recorded in SG&A. The remainder of these charges were recorded in Other non-operating income, net. The following
table presents restructuring activity for the 	three 	months ended 	September 30, 2019:
Reserve Balance 	Three Months Ended September 30, 2019 	Reserve Balance
June 30, 2019 	Charges 	Cash Spent 	Charges Against Assets 	September 30, 2019
Separations 	$ 	280 	$ 	34 	$ 	(60) 	$ 	— 	$ 	254
Asset-related costs 	— 	45 	— 	(45) 	—
Other costs 	188 	14 	(25) 	— 	177
Total 	$ 	468 	$ 	93 	$ 	(85) 	$ 	(45) 	$ 	431
Separation Costs
Employee separation charges for the 	three 	month period ended 	September 30, 2019 	relate to severance packages for approximately 	180 	employees. The packages
were primarily voluntary and the amounts were calculated based on salary levels and past service periods. Severance costs related to voluntary separations are
generally charged to earnings when the employee accepts the offer.
Asset-Related Costs
Asset-related costs consist of both asset write-downs and accelerated depreciation. Asset write-downs relate to the establishment of a new fair value basis for assets
held-for-sale or disposal. These assets were written down to the lower of their current carrying basis or amounts expected to be realized upon disposal, less minor
disposal costs. Charges for accelerated depreciation relate to long-lived assets that will be taken out of service prior to the end of their normal service period. These
assets relate primarily to manufacturing consolidations and technology standardizations. The asset-related charges will not have a significant impact on future
depreciation charges.
Other Costs
Other restructuring-type charges are incurred as a direct result of the restructuring program. Such charges primarily include asset removal and termination of
contracts related to supply chain optimization.
Consistent with our historical policies for ongoing restructuring-type activities, the restructuring program charges are funded by and included within Corporate for
both management and segment reporting. Accordingly, all of the charges under the program are included within the Corporate reportable segment. However, for
informative purposes, the following table summarizes the total restructuring costs related to our reportable segments:
Three Months Ended
September 30, 2019
Beauty 	$ 	8
Grooming 	18
Health Care 	12
Fabric & Home Care 	4
Baby, Feminine & Family Care 	20
Corporate 	(1) 	31
Total Company 	$ 	93
(1) 	Corporate includes costs related to allocated overheads, including charges related to our Market Operations, Global Business Services and Corporate Functions
activities.
Amounts in millions of dollars unless otherwise specified.

-- 14 of 45 --

10. Leases
The Company determines whether a contract contains a lease at the inception of a contract by determining if the contract conveys the right to control the use of
identified property, plant or equipment for a period of time in exchange for consideration. We lease certain real estate, machinery, equipment, vehicles and office
equipment for varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these
options are included within the lease term when it has become reasonably certain that the Company will exercise such options. The incremental borrowing rate
utilized to calculate our lease liabilities is based on the information available at commencement date, as most of the leases do not provide an implicit borrowing
rate. The Company does not have any material financing lease or sublease activities.
The Company incurred lease expense for operating leases of 	$85 	for the three months ended 	September 30, 2019. Total cash paid related to leases during the three
months ended 	September 30, 2019 	was 	$71, including amounts expensed and amounts capitalized. Commitments related to finance leases are not material. Short-
term leases, defined as leases with initial terms of 12 months or less, are not reflected on the Consolidated Balance Sheets. Lease expense for such short-term leases
is not material. The most significant assets in our leasing portfolio relate to real estate and vehicles. For purposes of calculating lease liabilities for such leases, we
have combined lease and non-lease components.
The right-of-use assets obtained in exchange for new lease liabilities was $9 	for the three months ended 	September 30, 2019.
Supplemental balance sheet and other information related to leases is as follows:
September 30, 2019
Operating leases:
Other noncurrent assets 	$ 	887
Accrued and other liabilities 	263
Other noncurrent liabilities 	630
Total operating lease liabilities 	$ 	893
Weighted average remaining lease term:
Operating leases 	7 years
Weighted average discount rate:
Operating leases 	4.3%
At 	September 30, 2019, future payments of operating lease liabilities were as follows:
Operating Leases
September 30, 2019
1 year 	$ 	263
2 years 	177
3 years 	158
4 years 	134
5 years 	114
Over 5 years 	218
Total lease payments 	1,064
Less: Interest 	(171)
Present value of lease liabilities 	$ 	893
Amounts in millions of dollars unless otherwise specified.

-- 15 of 45 --

As of 	June 30, 2019, minimum lease payments under non-cancelable operating leases by fiscal year were expected to be:
Operating Leases
June 30, 2019
2020 	$ 	263
2021 	209
2022 	165
2023 	141
2024 	121
After 2024 	244
Total lease payments 	$ 	1,143
11. Commitments and Contingencies
Litigation
We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and
trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While considerable
uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially affect our financial
position, results of operations or cash flows.
We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the
environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of
environmental remediation will materially affect our financial position, results of operations or cash flows.
Income Tax Uncertainties
The Company is present in approximately 	70 	countries and over 	150 	taxable jurisdictions and, at any point in time, has 	40–50 	jurisdictional audits underway at
various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and may
not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis and are
adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations. Such
adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2008 and forward. We are generally not able to reliably estimate
the ultimate settlement amounts until the close of the audit. Based on information currently available, we anticipate that over the next 12 month period, audit
activity could be completed related to uncertain tax positions in multiple jurisdictions for which we have accrued existing liabilities of approximately 	$140,
including interest and penalties.
Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the year ended 	June 30,
2019.
Amounts in millions of dollars unless otherwise specified.

-- 16 of 45 --

12. Merck Acquisition
On November 30, 2018, we completed our acquisition of the over the counter (OTC) healthcare business of Merck KGaA (Merck OTC) for 	$3.7 billion 	(based on
exchange rates at the time of closing) in an all-cash transaction. This business primarily sells OTC consumer healthcare products, mainly in Europe, Latin America
and Asia markets. The results of Merck OTC, which are not material to the Company, are reported in our consolidated financial statements beginning December 1,
2018.
The following table presents the preliminary allocation of purchase price related to the Merck OTC business as of the date of acquisition. The preliminary
allocation of the purchase price is based on the best estimates of management and is subject to revision based on final determination of fair values of the assets and
liabilities acquired, which will be finalized during the quarter ended December 31, 2019, as we complete our analysis of the underlying assets and acquired
liabilities, such as pensions, litigation cases, environmental issues and tax positions.
Amounts in millions 	November 30, 2018
Current assets 	$ 	420
Property, plant and equipment 	121
Intangible assets 	2,134
Goodwill 	2,085
Other non-current assets 	209
Total assets acquired 	$ 	4,969
Current liabilities 	$ 	233
Deferred income taxes 	764
Non-current liabilities 	95
Total liabilities acquired 	$ 	1,092
Noncontrolling interest 	(1) 	$ 	169
Net assets acquired 	$ 	3,708
(1) 	Represents a 	48% 	minority ownership interest in the Merck India company.
The acquisition resulted in 	$2.1 billion 	in goodwill, of which approximately 	$180 million 	is expected to be deductible for tax purposes. All of this goodwill was
allocated to the Health Care Segment.
We have preliminarily estimated the fair value of Merck OTC’s identifiable intangible assets as 	$2.1 billion. The preliminary allocation of identifiable intangible
assets and their average useful lives is as follows:
Amounts in millions 	Estimated Fair Value
Avg Remaining
Useful Life
Intangible assets with determinable lives
Brands 	$ 	701 	14
Patents and technology 	162 	10
Customer relationships 	325 	20
Total 	$ 	1,188 	15
Intangible assets with indefinite lives
Brands 	946
Total intangible assets 	$ 	2,134
Amounts in millions of dollars unless otherwise specified.

-- 17 of 45 --

The majority of the intangible valuation relates to brand intangibles. Our preliminary assessment as to brand intangibles that have an indefinite life and those that
have a definite life was based on a number of factors, including competitive environment, market share, brand history, product life cycles, operating plan and the
macroeconomic environment of the countries in which the brands are sold. The indefinite-lived brand intangibles include Neurobion and Dolo Neurobion. The
definite-lived brand intangibles primarily include regional or local brands. The definite-lived brand intangibles have estimated lives ranging from 	10 	to 	20 	years.
The technology intangibles are related to R&D and manufacturing know-how; these intangibles have a 	10 	year estimated life. The customer relationships
intangibles have a 	20 	year estimated life and reflect the 	historical and projected attrition rates for Merck OTC’s relationships with health care professionals,
retailers and distributors.
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and
expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may appear throughout this report, including without limitation, the following sections: “Management's Discussion and Analysis,” “Risk Factors,” and
"Notes 4 and 11 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and
similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause
results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise publicly any forward-
looking statements, whether because of new information, future events or otherwise.
Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial
risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local, regional
or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to affect the expected
share repurchases and dividend payments; (3) the ability to manage disruptions in credit markets or changes to our credit rating; (4) the ability to maintain key
manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to
manage disruption of business due to factors outside of our control, such as natural disasters and acts of war or terrorism; (5) the ability to successfully manage cost
fluctuations and pressures, including prices of commodities and raw materials, and costs of labor, transportation, energy, pension and healthcare; (6) the ability to
stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits and technological
advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and global competitors in new and existing sales channels,
including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products; (8) the ability to manage and
maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including
concerns about safety, quality, ingredients, efficacy or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and
operational risk associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11)
the ability to rely on and maintain key company and third party information technology systems, networks and services, and maintain the security and functionality
of such systems, networks and services and the data contained therein; (12) the ability to successfully manage uncertainties related to changing political conditions
(including the United Kingdom’s decision to leave the European Union) and potential implications such as exchange rate fluctuations and market contraction; (13)
the ability to successfully manage regulatory and legal requirements and matters (including, without limitation, those laws and regulations involving product
liability, product and packaging composition, intellectual property, antitrust, data protection, tax, environmental, and accounting and financial reporting) and to
resolve pending matters within current estimates; (14) the ability to manage changes in applicable tax laws and regulations including maintaining our intended tax
treatment of divestiture transactions; (15) the ability to successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve
the Company’s overall business strategy and financial objectives, without impacting the delivery of base business objectives; and (16) the ability to successfully
achieve productivity improvements and cost savings and manage ongoing organizational changes, while successfully identifying, developing and retaining key
employees, including in key growth markets where the availability of skilled or experienced employees may be limited. 	A detailed discussion of risks and
uncertainties that could cause actual results and events to differ materially from those projected herein, is included in the section titled “Economic Conditions and
Uncertainties” and the section titled “Risk Factors” (Part II, Item 1A) of this Form 10-Q.
The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of operations
and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in conjunction
with, our Consolidated Financial Statements and accompanying notes.
The MD&A is organized in the following sections:
• 	Overview
• 	Summary of Results – 	Three 	Months Ended 	September 30, 2019
• 	Economic Conditions and Uncertainties
• 	Results of Operations – 	Three Months Ended September 30, 2019
• 	Business Segment Discussion – 	Three Months Ended September 30, 2019
• 	Liquidity and Capital Resources
• 	Reconciliation of Measures Not Defined by U.S. GAAP
Throughout the MD&A, we refer to measures used by management to evaluate performance, including unit volume growth, net sales and net earnings. We also
refer to a number of financial measures that are not defined under accounting principles generally accepted in the United States of America (U.S. GAAP), including
organic sales growth, core net earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the end of the
MD&A provides the definition of these non-GAAP measures as well as details on the use and the derivation of these measures.
Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the
availability and comparability of share and consumption information. References to market share and market consumption in the MD&A are based on a
combination of vendor purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent
the percentage of sales in dollar terms on a constant currency basis of our products, relative to all product sales in the category. The Company measures fiscal-year-
to-date market shares through the most recent period for which market share data is available, which typically reflects a lag time of one or two months.
OVERVIEW

-- 18 of 45 --

P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to our
consumers around the world. Our products are sold in more than 	180 	countries and territories, primarily through mass merchandisers, e-commerce, grocery stores,
membership club stores, drug stores, department stores, distributors, wholesalers, baby stores, specialty beauty stores, high-frequency stores and pharmacies. We
also sell direct to consumers. We have on-the-ground operations in approximately 	70 	countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our
products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we compete
are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We are well positioned in the industry segments and
markets in which we operate, often holding a leadership or significant market share position.
The table below provides detail on our reportable segments, including the product categories and brand composition within each segment.
Reportable Segments 	Product Categories (Sub-Categories) 	Major Brands
Beauty
Hair Care (Conditioner, Shampoo, Styling Aids, Treatments) Head & Shoulders, Herbal
Essences, Pantene, Rejoice
Skin and Personal Care (Antiperspirant and Deodorant, Personal Cleansing, Skin Care) Olay, Old Spice, Safeguard, SK-
II, Secret
Grooming Grooming 	(1) 	(Shave Care - 	Female Blades & Razors, Male Blades & Razors, Pre- and
Post-Shave Products, Other Shave Care; 	Appliances) Braun, Gillette, Venus
Health Care
Oral Care (Toothbrushes, Toothpaste, Other Oral Care) 	Crest, Oral-B
Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health Care)
Metamucil, Neurobion, Pepto
Bismol, Vicks
Fabric & Home Care
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents) 	Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze,
Mr. Clean, Swiffer
Baby, Feminine & Family Care
Baby Care (Baby Wipes, Taped Diapers and Pants) 	Luvs, Pampers
Feminine Care (Adult Incontinence, Feminine Care) Always, Always Discreet,
Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) 	Bounty, Charmin, Puffs
(1) 	The Grooming product category is comprised of the Shave Care and Appliances operating segments.
The following table provides the percentage of net sales and net earnings by reportable business segment for the 	three 	months ended 	September 30, 2019
(excluding net sales and net earnings in Corporate):
Three Months Ended September 30, 2019
Net Sales 	Net Earnings
Beauty 	20% 	25%
Grooming 	9% 	10%
Health Care 	12% 	11%
Fabric & Home Care 	33% 	29%
Baby, Feminine & Family Care 	26% 	25%
Total Company 	100% 	100%
SUMMARY OF RESULTS
Following are highlights of results for the 	three 	months ended 	September 30, 2019 	versus the 	three 	months ended 	September 30, 2018:
• 	Net sales increased 7% to 	$17.8 billion, driven by a 20% increase in Health Care, a high single digits increase in Beauty and mid-single digits increases in
Fabric & Home Care and Baby, Feminine & Family Care, partially offset by a low single digit decline in Grooming. Organic sales, which exclude the impacts
of acquisitions and divestitures and foreign exchange, 	increased 7%, driven by a double digits increase in Beauty, high single digits increases in Health Care

-- 19 of 45 --

and Fabric & Home Care, a mid-single digit increase in Baby, Feminine & Family Care and a low single digit increase in Grooming.
• 	Unit volume increased 	5%, with organic volume up 	4%. Volume increased high teens in Health Care, mid-single digits in Fabric & Home Care, and low single
digits in Beauty and in Baby, Feminine & Family Care. Volume decreased low single digits in Grooming. Excluding the impacts of the Merck OTC
acquisition, organic volume increased mid-single digits in Health Care.
• 	Net earnings were 	$3.6 billion, an increase of $0.4 billion or 13% versus the prior year due to the increase in net sales, an increase in operating margin and a
reduction in the current year income tax rate, partially offset by the base period gain on dissolution of the PGT Healthcare partnership.
• 	Net earnings attributable to Procter & Gamble increased 	$0.4 billion 	or 	12% 	versus the prior year to 	$3.6 billion.
• 	Diluted net earnings per share increased 	11% 	to 	$1.36 	due primarily to the increase in net earnings.
• 	Core net earnings attributable to Procter & Gamble, which represents net earnings excluding incremental restructuring charges in both periods and the base
period gain on the dissolution of the PGT Healthcare partnership, increased 24% to $3.6 billion. Core net earnings per share increased 	22% 	to 	$1.37 	due
primarily to the increase in Core net earnings.
• 	Operating cash flow was 	$4.2 billion. Adjusted free cash flow, which is operating cash flow less capital expenditures and certain other impacts, was 	$3.3
billion. Adjusted free cash flow productivity was 	91%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
Global Economic Conditions. Our products are sold in numerous countries across North America, Europe, Latin America, Asia and Africa with more than half
our sales generated outside the United States. As such, we are exposed to and impacted by global macroeconomic factors, U.S. and foreign government policies
and foreign exchange fluctuations. Current macroeconomic factors remain dynamic, and any causes of market size contraction, such as reduced GDP in
commodity-dependent economies, greater political unrest in the Middle East, Central & Eastern Europe, Greater China and the Korean peninsula, economic
uncertainty related to the execution of the United Kingdom's exit from the European Union, political instability in certain Latin American markets and overall
economic slowdowns, could reduce our sales or erode our operating margin, in either case reducing our earnings.
Changes in Costs. Our costs are subject to fluctuations, particularly due to changes in commodity prices, transportation costs and our own productivity efforts. We
have significant exposures to certain commodities, in particular, certain oil-derived materials like resins and paper-based materials like pulp, and volatility in the
market price of these commodity input materials has a direct impact on our costs. If we are unable to manage commodity fluctuations through pricing actions, cost
savings projects and sourcing decisions, as well as through consistent productivity improvements, it may adversely impact our gross margin, operating margin and
net earnings. Sales could also be adversely impacted following pricing actions if there is a negative impact on consumption of our products. We strive to
implement, achieve and sustain cost improvement plans, including outsourcing projects, supply chain optimization and general overhead and workforce
optimization. As discussed later in this MD&A, in 2012 we initiated overhead and supply chain cost improvement projects. In fiscal 2017, we communicated
specific elements of an additional multi-year cost reduction program which is resulting in enrollment reductions and other savings. If we are not successful in
executing and sustaining these changes, there could be a negative impact on our operating margin and net earnings.
Foreign Exchange. We have both translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate impacts
of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1) the impact
from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances
denominated in currencies other than the functional currency. In four of the past five fiscal years, as well as the current year, the U.S. dollar has strengthened versus
a number of foreign currencies leading to lower sales and earnings from these foreign exchange impacts. Certain countries experiencing significant exchange rate
fluctuations, like Argentina, Brazil, China and the United Kingdom have previously had, and could in the future have, a significant impact on our sales, costs and
earnings. Increased pricing in response to certain fluctuations in foreign currency exchange rates may offset portions of the currency impacts but could also have a
negative impact on consumption of our products, which would affect our sales and profits.
Government Policies. Our net earnings could be affected by changes in U.S. or foreign government tax policies, for example, the U.S. Tax Act enacted in
December 2017, and the current work being led by the OECD for the G20 focused on "Addressing the Challenges of the Digitalization of the Economy." The
breadth of this project extends beyond pure digital businesses and is likely to impact all multinational businesses by redefining jursidictional taxing rights.
Additionally, we attempt to carefully manage our debt, currency and other exposures in certain countries with currency exchange, import authorization and pricing
controls, such as Nigeria, Algeria, Egypt, Argentina and Turkey. Further, our earnings and sales could be affected by changes to international trade agreements in
North America and elsewhere, including increases of import tariffs, both currently effective and future potential changes. Changes in government policies in these
areas might cause an increase or decrease in our sales, operating margin and net earnings.
For information on risk factors that could impact our results, please refer to “Risk Factors” in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended
June 30, 2019.
RESULTS OF OPERATIONS – Three Months Ended 	September 30, 2019
The following discussion provides a review of results for the three months ended 	September 30, 2019 	versus the three months ended 	September 30, 2018.
Three Months Ended September 30
Amounts in millions, except per share amounts 	2019 	2018 	% Chg
Net sales 	$17,798 	$16,690 	7%
Operating income 	4,290 	3,554 	21%
Net earnings 	3,617 	3,211 	13%
Net earnings attributable to Procter & Gamble 	3,593 	3,199 	12%
Diluted net earnings per common share 	1.36 	1.22 	11%
Core net earnings per common share 	1.37 	1.12 	22%

-- 20 of 45 --

Three Months Ended September 30
COMPARISONS AS A PERCENTAGE OF NET SALES 	2019 	2018 	Basis Pt Chg
Gross profit 	51.0% 	49.2% 	180
Selling, general & administrative expense 	26.9% 	27.9% 	(100)
Operating income 	24.1% 	21.3% 	280
Earnings before income taxes 	24.4% 	23.6% 	80
Net earnings 	20.3% 	19.2% 	110
Net earnings attributable to Procter & Gamble 	20.2% 	19.2% 	100
Net Sales
Net sales for the quarter 	increased 7% to 	$17.8 billion 	including a 2% negative impact from foreign exchange. Unit volume 	increased 5%. Excluding the impacts of
acquisitions and divestitures, organic volume increased 4%. Increased pricing had a 1% favorable impact to net sales. Mix was a 2% positive impact to net sales,
driven by disproportionate organic growth of Japan, Skin & Personal Care and Personal Health Care categories, all of which have higher than company average
selling prices. Volume increased high teens in Health Care, increased mid-single digits in Fabric & Home Care and increased low single digits in Beauty and in
Baby, Feminine & Family Care. Volume decreased low-single digits in Grooming. Excluding the impacts of the Merck OTC acquisition, Health Care organic
volume increased mid-single digits. On a regional basis, volume growth was driven by high single digits increases in Latin America and in Asia Pacific, primarily
due to inventory build by retailers in Japan in advance of a VAT increase effective October 2019, and mid-single digits increases in North America, Europe,
Greater China, and India, Middle East and Africa (IMEA). Excluding the impact of minor acquisitions and divestitures, organic volume increased mid-single digits
in Latin America and increased low single digits in Greater China, Europe and IMEA. Organic sales increased 	7% 	on a 	4% 	increase in organic volume.
Net Sales Change Drivers 2019 vs. 2018 (Three Months Ended September 30) 	(1)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange 	Price 	Mix 	Other 	(1)
Net Sales
Growth 	(2)
Beauty 	3% 	3% 	(2)% 	3% 	4% 	—% 	8%
Grooming 	(1)% 	(1)% 	(2)% 	1% 	—% 	—% 	(2)%
Health Care 	17% 	6% 	(2)% 	1% 	2% 	2% 	20%
Fabric & Home Care 	6% 	6% 	(1)% 	—% 	1% 	—% 	6%
Baby, Feminine & Family Care 	2% 	2% 	(1)% 	2% 	1% 	—% 	4%
Total Company 	5% 	4% 	(2)% 	1% 	2% 	1% 	7%
(1) 	Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
(2) 	Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Operating Costs
Gross margin 	increased 180 basis points to 51.0% 	of net sales for the quarter. Gross margin benefited from:
• 	90 basis points of gross manufacturing cost savings projects (80 basis points net of product and packaging reinvestments),
• 	70 basis points of positive pricing impacts,
• 	40 basis points of lower commodity costs, and
• 	50 basis points of other benefits
These benefits were partially offset by a 10 basis point decline from unfavorable foreign exchange and a 50 basis point net decline from unfavorable product mix
(primarily mix within segments due to the growth of lower margin product forms and large sizes in certain categories and due to the disproportionate growth of the
Fabric Care category which is one of our largest categories and has lower than company-average margins).
Total SG&A spending increased 3% to $4.8 billion due to increases in marketing spending and overhead costs, partially offset by a reduction in other operating
costs. SG&A as a percentage of net sales 	decreased 100 basis points to 26.9% 	due to a decrease in overhead, marketing spending and other operating costs as a
percentage of net sales. Marketing spending as a percentage of net sales decreased 20 basis points due to the positive scale impacts of the net sales increase and
savings in agency compensation, production costs and advertising spending, partially offset by reinvestments in media and other marketing spending. Overhead
costs as a percentage of net sales decreased 30 basis points driven by the positive scale impacts of the net sales increase, productivity savings and lower
restructuring charges versus the base period, partially offset by inflation, higher incentive compensation costs and other cost increases. Other net operating costs as
a percentage of net sales decreased 50 basis points due to a reduction in foreign exchange transaction charges and gains from legal settlements. Productivity-driven
cost savings delivered 70 basis points of benefit in SG&A.
Non-Operating Expenses and Income
Interest expense was 	$108 million 	for the quarter, a decrease of $21 million versus the prior year period due to a decrease in average debt balances. Interest income
was 	$58 million 	for the quarter, a 	$5 million 	increase versus the prior year period due to an increase in higher yield investment securities balances. Other non-
operating income was 	$103 million, a decrease of 	$359 million 	due to the base period gain from the dissolution of the PGT Healthcare partnership.
Income Taxes
For the three months ended 	September 30, 2019 	the effective tax rate decreased 180 basis points versus the prior year period to 16.7% due to:
• 	a 150 basis-point reduction from increased excess tax benefits of share-based compensation (200 basis points in the current year versus 50 basis points in the
prior year),
• 	a 120 basis-point reduction from a non-recurring tax benefit arising from a simplification of our legal entity structure,
• 	a 90 basis-point reduction from favorable impacts from geographic mix of earnings,
• 	partially offset by a 180 basis-point increase related to the prior year tax impact of the gain on the dissolution of the PGT Healthcare partnership.
Net Earnings
Operating income increased $736 million, or 21% to $4.3 billion due to the net sales increase, the increase in gross margins and the reduction in SG&A as a
percentage of sales, all of which are described above. Net earnings 	increased $406 million or 13% to $3.6 billion 	due to the increase in operating income and the

-- 21 of 45 --

lower tax rates as described above, partially offset by the base period gain on the PGT Healthcare partnership dissolution. Foreign exchange had a negative impact
of $50 million on net earnings for the quarter, including both transactional charges and translational impacts from converting earnings from foreign subsidiaries to
U.S. dollars. Net earnings attributable to Procter & Gamble increased $394 million or 12% to $3.6 billion for the quarter. Diluted net earnings per share 	increased
11% to $1.36. Core net earnings per share 	increased 22% to $1.37. Core net earnings per share represents diluted net earnings per share excluding the incremental
restructuring charges in both periods related to our productivity and cost savings plans and the gain on dissolution of the PGT Healthcare partnership in the base
period.
Amounts in millions of dollars unless otherwise specified.

-- 22 of 45 --

BUSINESS SEGMENT DISCUSSION – 	Three 	Months Ended 	September 30, 2019
The following discussion provides a review of results by reportable business segment. Analysis of the results for the 	three 	months period ended 	September 30,
2019 	is provided based on a comparison to the same 	three 	months period ended 	September 30, 2018. The primary financial measures used to evaluate segment
performance are net sales and net earnings. The table below provides supplemental information on net sales and net earnings by reportable business segment for the
three 	months ended 	September 30, 2019 	versus the comparable prior year period (dollar amounts in millions):
Three Months Ended September 30, 2019
Net Sales
% Change
Versus Year Ago
Earnings/(Loss) Before Income
Taxes
% Change
Versus Year
Ago 	Net Earnings
% Change
Versus Year
Ago
Beauty 	$ 	3,552 	8 	% 	$ 	1,092 	15% 	$ 	874 	15%
Grooming 	1,531 	(2)% 	426 	2% 	353 	4%
Health Care 	2,221 	20 	% 	540 	23% 	401 	21%
Fabric & Home Care 	5,832 	6 	% 	1,338 	17% 	1,028 	17%
Baby, Feminine & Family Care 	4,567 	4 	% 	1,134 	26% 	871 	26%
Corporate 	95 	N/A 	(187) 	N/A 	90 	N/A
Total Company 	$ 	17,798 	7 	% 	$ 	4,343 	10% 	$ 	3,617 	13%
Beauty
Three months ended 	September 30, 2019 	compared with three 	months ended 	September 30, 2018
Beauty net sales 	increased 8% to 	$3.6 billion 	during the 	first fiscal quarter 	on 	a 3% increase in unit volume. Favorable product mix added 4% to net sales due to the
disproportionate growth of the Skin and Personal Care category, including the super-premium SK-II brand, which has higher than segment average selling prices.
Higher pricing increased net sales by 3%. Unfavorable foreign exchange impacts reduced net sales by 2%. Organic sales 	increased 10%. Global market share of the
Beauty segment 	increased 0.3 points. Volume growth was driven by a mid-single digit increase in North America, Asia Pacific, Latin America and IMEA and a
low single digits increase in Europe. The volume increase in Asia Pacific was primarily driven by an increase in retailer inventories in Japan prior to a VAT
increase in October 2019.
• 	Volume in Hair Care 	increased low single digits. Increased volume was driven by mid-single digits growth in North America, Asia Pacific, Europe, Latin
America and IMEA (due to product innovation, market growth and Japan retailer inventory increase), partially offset by a low single digits decline in Greater
China due to competitive activities. Excluding the impact of minor brand acquisitions, volume increased low single digits in North America. Global market
share of the Hair Care category 	was unchanged.
• 	Volume in Skin and Personal Care 	increased mid-single digits. Volume increased in all regions, led by a high single digits increase in Greater China and mid-
single digits increases in North America and Latin America driven by premium innovation. Global market share of the Skin and Personal Care category
increased more than half a point.
Net earnings 	increased 15% to 	$874 million 	due to the increase in net sales and a 150 basis-point increase in net earnings margin. The net earnings margin
increased primarily due to a reduction in SG&A as a percentage of sales, along with an increase in gross margin. The gross margin increase was primarily driven
by increased pricing, partially offset by negative foreign exchange impacts and other hurts related to new manufacturing startup costs. The reduction in SG&A as a
percentage of sales was primarily due to the positive scale impacts of the net sales increase.
Grooming
Three months ended 	September 30, 2019 	compared with three 	months ended 	September 30, 2018
Grooming net sales 	decreased 2% to 	$1.5 billion 	during the 	first fiscal quarter 	on 	a 1% decrease in unit volume. Unfavorable foreign exchange had a negative 2%
impact on net sales. Pricing had a positive 1% impact on net sales. Organic sales 	increased 1%. Global market share of the Grooming segment 	decreased 0.4 points.
The volume decrease was driven by a high single digits decline in North America, partially offset by a mid-single digits increase in Greater China and a low single
digits increase in Latin America.
• 	Shave Care volume 	decreased low single digits. The volume decrease was driven by a high single digits decline in North America due to competitive activity,
partially offset by a mid-single digits increase in Greater China and low single digit increases in Latin America and Asia Pacific due to product innovation.
Global market share of the Shave Care category 	was unchanged.

-- 23 of 45 --

• 	Volume in Appliances decreased mid-single digits. A decline of more than 20% in Asia Pacific (due to market contraction, competitive activities and a
reduction in trade inventories), was partially offset by mid-single digit volume increase in Greater China due to innovation. Global market share of the
Appliances category 	was unchanged.
Net earnings 	increased 4% to 	$353 million 	due to a 130 basis-point increase in net earnings margin, partially offset by the reduction in net sales. Net earnings
margin increased primarily due to a reduction in SG&A as a percentage of net sales and a reduction in effective tax rates, partially offset by a reduction in gross
margin. Gross margin declined due to the negative impact of unfavorable mix (due to the growth of lower margin products), partially offset by the positive impacts
of manufacturing cost savings and increased pricing. SG&A as a percentage of net sales decreased primarily due to a favorable legal settlement in the current
period and reduction in overhead costs due to productivity savings, partially offset by the negative scale impacts of the net sales decrease.
Health Care
Three months ended 	September 30, 2019 	compared with three 	months ended 	September 30, 2018
Health Care net sales 	increased 20% to 	$2.2 billion 	during the 	first fiscal quarter 	on 	a 17% increase in unit volume. Excluding the impact of the Merck OTC
consumer healthcare acquisition, organic sales increased 9% and organic volume increased 6%. Unfavorable foreign exchange impacts decreased net sales by 2%.
Higher pricing increased net sales by 1%. Favorable mix increased net sales by 2% due to the disproportionate organic growth of premium products and the North
America region which have higher than segment average margins. Global market share of the Health Care segment 	increased 0.3 points. Volume increased in all
regions, led by over 20% growth in Europe, Latin America, IMEA and Asia Pacific and high single digits growth in North America. Excluding the impact of the
Merck OTC consumer healthcare acquisition, organic volume increased high single digits in IMEA and in Latin America and increased low single digits in Europe
and in Asia Pacific.
• 	Oral Care volume 	increased mid-single digits. Increased volume was driven by high teens growth in IMEA and high single digits growth in North America,
Asia Pacific and Latin America due to innovation and market growth. Global market share of the Oral Care category 	increased nearly half a point.
• 	Volume in Personal Health Care increased more than 50% versus the prior year period. Excluding the impact of the Merck OTC consumer healthcare
acquisition, organic volume increased high single digits. The organic volume increase was driven by over 20% growth in Europe and double digits growth in
North America (due to innovation and higher retailer inventory build for the cough/cold season versus the year ago period), partially offset by double digit
volume declines in Asia Pacific due to devaluation-related price increases. Global market share of the Personal Health Care category 	increased slightly.
Net earnings 	increased 21% to 	$401 million, primarily due to the increase in net sales. Net earnings margin increased 10 basis points as an increase in gross margin
was largely offset by an increase in SG&A as a percentage of sales and an increase in income tax rates. The increase in gross margin was driven by the positive
impacts of increased pricing and favorable mix due to the disproportionate growth of the North America region which has higher than segment-average margins,
partially offset by the mix impact of the Merck OTC consumer healthcare acquisition. SG&A as a percentage of net sales increased primarily due to an increase in
overheads and other operating expenses caused by the impact of the Merck OTC consumer healthcare acquisition, partially offset by the positive scale benefits of
the net sales increase.
Fabric & Home Care
Three months ended 	September 30, 2019 	compared with three months ended 	September 30, 2018
Fabric & Home Care net sales 	increased 6% to 	$5.8 billion 	during the 	first fiscal quarter 	on 	a 6% increase in unit volume. Unfavorable foreign exchange impacts
reduced net sales by 1%. Positive mix impacts increased net sales by 1% due to the disproportionate growth of premium products. Organic sales 	increased 8%.
Global market share of the Fabric & Home Care segment 	increased 0.7 points. Volume growth was driven by double digit increases in Asia Pacific, Greater China
and Latin America and mid-single digit increases in North America and Europe. The volume increase in Asia Pacific was partially driven by an increase in retailer
inventories in Japan prior to a VAT increase in October 2019.
• 	Fabric Care volume 	increased high single digits. Volume increased in all regions led by double digits growth in Asia Pacific, Greater China and Latin
America, high single digits growth in North America and mid-single digits growth in Europe. Growth was driven by product innovation, market growth and
the increase in Japan retailer inventories prior to a VAT increase. Global market share of the Fabric Care category 	increased half a point.
• 	Home Care volume 	increased low single digits. Excluding the impact of minor brand divestitures, organic volume increased mid-single digits. Increased
volume was driven by high single digits growth in Asia Pacific, mid-single digits growth in Europe and low single digits growth in North America. Volume
grew behind product innovation and the increase in Japan retailer inventories prior to a VAT increase. Global market share of the Home Care category
increased more than a point.

-- 24 of 45 --

Net earnings 	increased 17% to 	$1.0 billion 	due to the increase in net sales and a 160 basis point increase in net earnings margin. The net earnings margin increase
was primarily due to an increase in gross margin, along with a reduction in SG&A as a percentage of sales. The gross margin increase was driven by manufacturing
cost savings and reduction in commodity costs. SG&A expense as a percentage of net sales was down due to the positive scale benefits of the net sales increase.
Baby, Feminine & Family Care
Three months ended 	September 30, 2019 	compared with three 	months ended 	September 30, 2018
Baby, Feminine & Family Care net sales 	increased 4% to 	$4.6 billion 	during the 	first fiscal quarter 	on 	a 2% increase in unit volume. Unfavorable foreign exchange
impacts decreased net sales by 1%. Higher pricing increased net sales by 2%. Positive mix increased net sales by 1% due to the disproportionate growth of
premium products, which have higher than segment average margins. Organic sales 	increased 5%. Global market share of the Baby, Feminine & Family Care
segment 	decreased 0.5 points. Volume growth was driven by a mid-teens increase in Asia Pacific and a mid-single digit increase in North America, partially offset
by a low single digit decline in Europe and Latin America. Excluding the impact of minor brand acquisitions, organic volume increased low single digits in North
America. The volume increase in Asia Pacific was primarily driven by an increase in retailer inventories in Japan prior to a VAT increase in October 2019.
• 	Volume in Baby Care 	decreased low single digits. Volume decreased high single digits in Latin America and mid-single digits in Europe due to competitive
activity, devaluation related price increases and category contraction in certain markets. This was partially offset by high teens volume increase in Asia Pacific
due to the increase in Japan retailer inventories prior to the VAT increase, mid-single digit increase in Greater China, and low single digit increase in North
America due to product innovation. Global market share of the Baby Care category 	decreased more than a point.
• 	Volume in Feminine Care 	increased mid-single digits. Volume increased high single digits in IMEA and Latin America and increased mid-single digits in
Europe due to product innovation and adult incontinence category growth. Global market share of the Feminine Care category 	was unchanged.
• 	Volume in Family Care, which is predominantly a North American business, 	increased mid-single digits 	driven by product innovation, partially offset by
volume declines due to price increases. North America share of the Family Care category 	decreased nearly half a point.
Net earnings 	increased 26% to 	$871 million 	due to the increase in net sales and a 330 basis point increase in net earnings margin. Net earnings margin increased
primarily due to an increase in gross margin,along with a reduction in SG&A as a percentage of net sales. Gross margin increased due to manufacturing cost
savings projects, increased pricing and a reduction in commodity costs, partially offset by negative foreign exchange impacts. SG&A as a percentage of net sales
decreased due to reduced overhead costs, driven by productivity savings, partially offset by an increase in marketing spending as a percentage of net sales.
Corporate
Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include: the incidental businesses managed at
the corporate level; financing and investing activities; certain employee benefit costs; other general corporate items; the gains and losses related to certain divested
brands and categories; certain restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization. Corporate
also includes reconciling items to adjust the accounting policies used in the segments to U.S. GAAP. The most significant reconciling item includes income taxes
to adjust from blended statutory rates that are reflected in the segments to the overall Company effective tax rate.
Corporate net sales 	decreased $21 million 	to $95 million 	for the quarter ended 	September 30, 2019. Corporate net earnings 	decreased $121 million 	in the quarter
primarily due to the base period gain on the dissolution of the PGT Healthcare partnership, partially offset by lower restructuring charges versus the base period,
lower foreign exchange transactional charges, lower interest expense and a decrease in effective tax rates, all of which have been described above.
Restructuring Program to deliver Productivity and Cost Savings
In 2012, the Company initiated a productivity and cost savings plan to reduce costs and better leverage scale in the areas of supply chain, research and
development, marketing and overheads. 	The plan was designed to accelerate cost reductions by streamlining management decision making, manufacturing and
other work processes to fund the Company's growth strategy. In 2017, the Company communicated specific elements of an additional multi-year productivity and
cost savings program.
The current productivity and cost savings plan will further reduce costs in the areas of supply chain, certain marketing activities and overhead expenses. As part of
this plan, the Company incurred $1.8 billion in total before-tax restructuring costs across fiscal 2018 and fiscal 2019, with an additional amount of approximately
$0.6 billion expected in fiscal 2020. This program is expected to result in additional enrollment reductions, along with further optimization of the supply chain and
other manufacturing processes. Consistent with our historical policies for ongoing restructuring-type activities, the resulting charges are funded by and included
within Corporate for segment reporting.

-- 25 of 45 --

In addition to our restructuring programs, we have additional ongoing savings efforts in our supply chain, marketing and overhead areas that yield additional
benefits to our operating margins.
Refer to Note 9 in the Notes to the Consolidated Financial Statements for more details on the restructuring program.
LIQUIDITY & CAPITAL RESOURCES
Operating Activities
We generated 	$4.2 billion 	of cash from operating activities fiscal year to date, an increase of 	$602 million 	versus the prior year. Net earnings, adjusted for non-cash
items (depreciation and amortization, share-based compensation expense, deferred income taxes and gain on sale of assets), generated 	$3.9 billion 	of operating
cash flow. Working capital and other impacts generated 	$307 million 	of cash in the period. Accounts receivable increased, using 	$261 million 	of cash, primarily
due to sales growth and to a lesser extent, the extension of customer payment terms for seasonal products. These increases were partially offset by the timing of the
quarter-end (which fell on a Monday versus Sunday in the prior year end, resulting in greater collections). Inventory consumed 	$549 million 	of cash primarily to
support business growth, holiday seasonality builds in certain categories and product initiatives. Accounts payable, accrued and other liabilities increased,
generating 	$1.2 billion 	of cash. An increase in taxes payable drove approximately $900 million of the increase, including an approximate $500 million increase in
taxes payable related to the integration of Merck, which had no impact on operating cash flows, as there was an equal and offsetting release of a deferred tax
liability created on the acquisition of Merck. The remaining balance of the increase was primarily driven by an increase in payables to support the increase in
inventory and to a lesser extent extended payment terms with our suppliers, partially offset by the payment of prior fiscal year incentive compensation. All other
operating assets and liabilities used 	$35 million 	of cash.
Investing Activities
Investing activities generated 	$5.1 billion 	of cash fiscal year to date. Capital expenditures were 	$1.1 billion, or 	6.1% 	of net sales. We received 	$6.2 billion 	of cash
from sales and maturities of investment securities.
Financing Activities
Our financing activities used 	$4.1 billion 	of net cash fiscal year to date. We used 	$3.0 billion 	for treasury stock purchases, 	$1.9 billion 	for dividends and 	$61
million 	for debt repayments. Cash from the exercise of stock options and other impacts generated 	$875 million 	of cash.
As of 	September 30, 2019, our current liabilities exceeded current assets by 	$8.3 billion. We have short- and long-term debt to meet our financing needs. We
anticipate being able to support our short-term liquidity and operating needs largely through cash generated from operations. We have strong short- and long-term
debt ratings that have enabled and should continue to enable us to refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In
addition, we have agreements with a diverse group of financial institutions that, if needed, should provide sufficient credit funding to meet short-term financing
requirements.
RECONCILIATION OF MEASURES NOT DEFINED BY U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most closely
related GAAP measures. 	We believe that these measures provide useful perspective on underlying business results and trends (i.e., trends excluding non-recurring
or unusual items) and provide a supplemental measure of year-on-year results. The non-GAAP measures described below are used by management in making
operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors as they provide supplemental
information about business performance and provide investors a view of our business results through the eyes of management. These measures are also used to
evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not intended to be considered by the user in
place of the related GAAP measure, but rather as supplemental information to our business results. These non-GAAP measures may not be the same as similar
measures used by other companies due to possible differences in method and in the items or events being adjusted.
Organic sales growth: Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign exchange
from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by providing sales
growth on a consistent basis. This measure is used in assessing achievement of management goals for at-risk compensation.
Adjusted free cash flow: Adjusted free cash flow is defined as operating cash flow less capital spending and excluding payments for the transitional tax resulting
from the comprehensive U.S. legislation commonly referred to as the Tax Cuts and Jobs Act enacted in December 2017 (the U.S. Tax Act). Adjusted free cash flow
represents the cash that the Company is able to generate after taking into account planned maintenance and asset expansion. Management views adjusted free cash
flow as an important measure because it is one factor used in determining the amount of cash available for dividends, share repurchases, acquisitions and other
discretionary investments.
Adjusted free cash flow productivity: Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings. Management views
adjusted free cash flow productivity as a useful measure to help investors understand P&G’s ability to generate cash. Adjusted free cash flow productivity is used
by management in making operating decisions, allocating financial resources and for budget planning purposes. This measure is also used in assessing the
achievement of management goals for at-risk compensation. The Company's long-term target is to generate annual adjusted free cash flow productivity at or above
90 percent.
Core EPS: Core earnings per share, or Core EPS, is a measure of the Company's diluted net earnings per share adjusted as indicated. Management views this non-
GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used when evaluating senior management in
determining their at-risk compensation.
The Core earnings measures included in the following reconciliation tables refer to the equivalent GAAP measures adjusted as applicable for the following items:
Incremental Restructuring: The Company has had and continues to have an ongoing level of restructuring activities. Such activities have resulted in ongoing
annual restructuring related charges of approximately $250 - $500 million before tax. In 2012, the Company began a $10 billion strategic productivity and cost
savings initiative that included incremental restructuring activities. In 2017, we communicated details of an additional multi-year productivity and cost savings
plan. This results in incremental restructuring charges to accelerate productivity efforts and cost savings. The adjustment to Core earnings includes only the
restructuring costs above what we believe are the normal recurring level of restructuring costs.
Gain on Dissolution of PGT Healthcare Partnership: 	The Company finalized the dissolution of our PGT Healthcare partnership, a venture between the Company
and Teva Pharmaceuticals Industries, Ltd. (Teva) in the OTC consumer healthcare business, in the quarter ended September 30, 2018. The transaction was
accounted for as a sale of the Teva portion of the PGT business and resulted in the Company recognizing an after-tax gain on the dissolution of $353 million.
We do not view the above items to be part of our sustainable results and their exclusion from Core earnings measures provides a more comparable measure of year-

-- 26 of 45 --

on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation.
Organic sales growth:
Three Months Ended September 30, 2019 	Net Sales Growth 	Foreign Exchange Impact
Acquisition & Divestiture
Impact/Other 	(1) 	Organic Sales Growth
Beauty 	8% 	2% 	—% 	10%
Grooming 	(2)% 	2% 	1% 	1%
Health Care 	20% 	2% 	(13)% 	9%
Fabric & Home Care 	6% 	1% 	1% 	8%
Baby, Feminine & Family Care 	4% 	1% 	—% 	5%
Total Company 	7% 	2% 	(2)% 	7%
(1) 	Includes rounding impacts necessary to reconcile net sales to organic sales.
Adjusted free cash flow (dollar amounts in millions):
Three Months Ended September 30, 2019
Operating Cash Flow 	Capital Spending 	U.S. Tax Act Payments 	Adjusted Free Cash Flow
$4,169 	$(1,079) 	$215 	$3,305
Adjusted free cash flow productivity (dollar amounts in millions):
Three Months Ended September 30, 2019
Adjusted Free Cash Flow 	Net Earnings 	Adjusted Free Cash Flow Productivity
$3,305 	$3,617 	91%

-- 27 of 45 --

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
Three Months Ended September 30, 2019
AS REPORTED
(GAAP)
INCREMENTAL
RESTRUCTURING 	ROUNDING 	NON-GAAP (CORE)
COST OF PRODUCTS SOLD 	$ 	8,723 	$ 	(52) 	$ 	— 	$ 	8,671
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE 	4,785 	22 	— 	4,807
OPERATING INCOME 	4,290 	30 	— 	4,320
INCOME TAX 	726 	1 	— 	727
NET EARNINGS ATTRIBUTABLE TO P&G 	3,593 	31 	(1) 	3,623
Core EPS
DILUTED NET EARNINGS PER COMMON SHARE 	(1) 	$ 	1.36 	$ 	0.01 	$ 	— 	$ 	1.37
(1) 	Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
CORE NET EARNINGS ATTRIBUTABLE TO P&G 	24%
CORE EPS 	22%
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
Three Months Ended September 30, 2018
AS REPORTED
(GAAP)
INCREMENTAL
RESTRUCTURING
GAIN ON
DISSOLUTION OF
PGT PARTNERSHIP 	ROUNDING
NON-GAAP
(CORE)
COST OF PRODUCTS SOLD 	$ 	8,484 	$ 	(46) 	$ 	— 	$ 	— 	$ 	8,438
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE 	4,652 	(28) 	— 	1 	4,625
OPERATING INCOME 	3,554 	74 	— 	(1) 	3,627
INCOME TAX 	729 	6 	(2) 	1 	734
NET EARNINGS ATTRIBUTABLE TO P&G 	3,199 	69 	(353) 	— 	2,915
Core EPS
DILUTED NET EARNINGS PER COMMON SHARE 	(1) 	$ 	1.22 	$ 	0.03 	$ 	(0.14) 	$ 	0.01 	$ 	1.12
(1) 	Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.

-- 28 of 45 --

Item 3. 	Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the Company’s exposure to market risk since 	June 30, 2019. Additional information can be found in Note 7 - Risk
Management Activities and Fair Value Measurements of the Consolidated Financial Statements.
Item 4. 	Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s Chairman of the Board, President and Chief Executive Officer, David S. Taylor, and the Company’s Vice Chairman, Chief Operating Officer and
Chief Financial Officer, Jon R. Moeller, performed an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-
15(e) of the Securities Exchange Act of 1934 (“Exchange Act”)) as of the end of the period covered by this report. Messrs. Taylor and Moeller have concluded that
the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed in reports we file or submit under the
Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and
(2) accumulated and communicated to our management, including Messrs. Taylor and Moeller, to allow their timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the Company’s fiscal quarter ended 	September 30, 2019 	that have
materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. 	Legal Proceedings
The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including
antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters, and tax.
Item 1A. 	Risk Factors
For information on risk factors, please refer to “Risk Factors” in Part I, Item 1A of the Company's Form 10-K for the year ended June 30, 2019.
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds
ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of
Shares Purchased 	(1)
Average Price Paid
per Share 	(2)
Total Number of Shares Purchased as
Part of Publicly Announced Plans or
Programs 	(3)
Approximate Dollar Value of Shares That May
Yet Be Purchased Under Our Share
Repurchase Program
7/01/2019 - 7/31/2019 	10,793,321 	$114.19 	8,720,696 	(3)
8/01/2019 - 8/31/2019 	8,496,790 	$117.69 	8,496,790 	(3)
9/01/2019 - 9/30/2019 	8,187,635 	$122.14 	8,187,635 	(3)
Total 	27,477,746 	$117.64 	25,405,121
(1) 	All transactions were made in the open market with large financial institutions. This table excludes shares withheld from employees to satisfy minimum tax
withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third
party and does not repurchase stock in connection with cashless exercises.
(2) 	Average price paid per share for open market transactions is calculated on a settlement basis and excludes commission.
(3) 	On October 22, 2019, the Company stated that in fiscal year 2020 the Company expects to reduce outstanding shares through direct share repurchases at a
value of $6 to $8 billion, notwithstanding any purchases under the Company's compensation and benefit plans. Purchases may be made in the open market
and/or private transactions and purchases may be increased, decreased or discontinued at any time without prior notice. The share repurchases are authorized
pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a combination of operating cash flows and issuance of
long-term and short-term debt.

-- 29 of 45 --

Item 6. 	Exhibits
3-1 	Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the Board of
Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June 30, 2016)
3-2 	Regulations (as approved by the Board of Directors on April 8, 2016, pursuant to authority granted by shareholders at the annual meeting on
October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company's Form 10-K for the year ended June 30, 2016)
10-1 	Summary of the Company’s Short Term Achievement Reward Program* +
10-2 	The Procter & Gamble Performance Stock Program Summary* +
31.1 	Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2 	Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1 	Section 1350 Certifications – Chief Executive Officer +
32.2 	Section 1350 Certifications – Chief Financial Officer +
104 	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
101.SCH 	(1) 	Inline XBRL Taxonomy Extension Schema Document
101.CAL 	(1) 	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF 	(1) 	Inline XBRL Taxonomy Definition Linkbase Document
101.LAB 	(1) 	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE 	(1) 	Inline XBRL Taxonomy Extension Presentation Linkbase Document
* 	Compensatory plan or arrangement
+ 	Filed herewith
(1) 	Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

-- 30 of 45 --

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
THE PROCTER & GAMBLE COMPANY
October 22, 2019 	/s/ VALARIE L. SHEPPARD
Date 	(Valarie L. Sheppard)
Controller and Treasurer, and Executive Vice President -
Company Transition Leader

-- 31 of 45 --

EXHIBIT INDEX
Exhibit
3-1 	Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the Board of
Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June 30, 2016)
3-2 	Regulations (as approved by the Board of Directors on April 8, 2016, pursuant to authority granted by shareholders at the annual meeting on
October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company's Form 10-K for the year ended June 30, 2016)
10-1 	Summary of the Company’s Short Term Achievement Reward Program 	+
10-2 	The Procter & Gamble Performance Stock Program Summary 	+
31.1 	Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer 	+
31.2 	Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer 	+
32.1 	Section 1350 Certifications – Chief Executive Officer 	+
32.2 	Section 1350 Certifications – Chief Financial Officer 	+
104 	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
101.SCH 	(1) 	Inline XBRL Taxonomy Extension Schema Document
101.CAL 	(1) 	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF 	(1) 	Inline XBRL Taxonomy Definition Linkbase Document
101.LAB 	(1) 	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE 	(1) 	Inline XBRL Taxonomy Extension Presentation Linkbase Document
+ 	Filed herewith
(1) 	Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

-- 32 of 45 --

Exhibit (10-1)
Summary of the Company’s Short Term Achievement Reward Program

-- 33 of 45 --

SHORT TERM ACHIEVEMENT REWARD PROGRAM
(Effective July 1, 2019)
The Short Term Achievement Reward (“STAR”) Program is The Procter & Gamble Company’s (the “Company”) annual bonus program
designed to motivate and reward employees for achieving outstanding short term business results for the Company and its subsidiaries. STAR
awards are made pursuant to authority delegated to the Compensation & Leadership Development Committee (the “C&LD Committee”) by
the Board of Directors for awarding compensation to the Company’s principal officers and for making awards under the Procter & Gamble
2014 Stock and Incentive Compensation Plan (the “2014 Plan”) or any successor stock plan approved in accordance with applicable listing
standards.
I. 	ELIGIBILITY
Employees at Band 2 or above and who worked at least 28 days (four calendar weeks) during the applicable fiscal year are eligible to
participate. Eligible employees who do not work a full schedule (e.g., leaves of absence, disability, and less-than-full time schedules) in the
fiscal year in which the award is payable may have awards pro-rated.
II. 	Calculation
The individual STAR Award is calculated as follows:
(STAR Target) x [ (Business Unit Performance Factor 	x 70% weighting) + (Total Company Performance Factor 	X 30% weighting) ]
• 	The 	STAR Target 	for each participant is calculated as:
(Base Salary) x (STAR Target percent) where 	Base Salary 	at the end of the applicable fiscal year is used to calculate the STAR award.
Generally, the 	STAR Target Percent 	is dependent on the individual’s position and level (Band) in the organization. The STAR Target
percent for participants at Band 7 or above is set by the C&LD Committee. The STAR Target percent for all other participants is set by
the Chief Executive Officer, with the concurrence of the Chief Human Resources Officer, pursuant to authority delegated to them by
the C&LD Committee. If an individual’s position and/or level changes during a fiscal year, and that change results in a new STAR
Target Percent, the STAR Target Percent is pro-rated according to the amount of time in each position/level during the fiscal year.
• 	The 	Business Unit Performance Factor 	is weighted at 70% and is based on the fiscal year success for the appropriate STAR business
unit. The STAR business units are defined by the Chief Human Resources Officer and may consist of business categories, segments,
geographies, functions, organizations or a combination of one or more of these items. The STAR business units will be defined within
ninety (90) days of the beginning of the fiscal year, but may be adjusted as necessary to reflect business and/or organizational changes
(e.g., reorganization, acquisition, merger, divestiture, etc.). The Business Unit Performance Factors can range from 0% to 200% with a
target of 100%. In general, a committee consisting of at least two of the Chief Executive Officer, Chief Financial Officer, Chief Human
Resources Officer and/or the Chief Operating Officer (the “STAR Committee”), conducts a comprehensive retrospective assessment of
the fiscal year performance of each STAR business unit against previously established goals and relative to competition for one or more
of the following measures: Operating Total Shareholder Return, After Tax Profit, Free Cash Flow Productivity, Value Share, Organic
Sales, Internal controls, Accounts receivable 	,Inventory, 	Organization Head Self-Assessment, and Cross Organization Assessment. The
STAR Committee makes a recommendation of an appropriate Business Unit Performance Factor to the C&LD Committee. There may
also be other factors significantly affecting STAR business unit results positively or negatively which can be considered by the STAR
Committee when making its recommendation. No member of the STAR Committee makes any recommendation or determination as to
their own STAR award. As a result, there are certain instances in which a Business Unit

-- 34 of 45 --

Performance Factor recommendation to the C&LD Committee must be made exclusively by the Chief Executive Officer.
Business Unit leaders may then allocate the approved STAR Business Unit Factors among the divisions of the Business Unit to more
closely align the STAR award with performance, so long as the total expenditure does not exceed that approved by the STAR Committee
and no individual STAR award exceeds 200% of target.
• 	The 	Total Company Performance Factor 	is weighted at 30% and is based on the total Company’s success during the fiscal year and
ranges from 0% to 200%, with a target of 100%. The same Total Company Performance Factor is applied to all STAR award calculations,
regardless of STAR business unit. It is determined using a matrix which compares results against pre-established goals for fiscal year
organic sales growth and core earnings per share (“EPS”) growth for the fiscal year.
While the STAR Committee makes recommendations to the C&LD Committee regarding the Business Unit and Total Company performance
factors to be applied to all STAR awards (except those for the STAR Committee members), only the final award amounts for principal
officers are approved specifically by the C&LD Committee. The C&LD Committee has delegated the approval of STAR awards for other
participants to the Chief Executive Officer. The C&LD Committee has discretion to use, increase or decrease the performance factors
recommended by the STAR Committee and/or to choose not to pay STAR awards during a given year.
III. 	TIMING AND FORM
STAR awards are determined after the close of the fiscal year and are paid on or about September 15. The award form choices and relevant
considerations are explained to participants annually. Participants receive written notice of their award detailing the calculation and grant
letters for those employees who elect to receive awards in stock options
Generally, STAR awards are paid in cash. However, before the end of the calendar year preceding the award date, eligible participants can
elect to receive their STAR award in forms other than cash. Alternatives to cash include stock options, stock appreciation rights (“SARS”),
local deferral programs (depending on local regulations in some countries) and/or deferred compensation (for employees eligible to
participate in the Executive Deferred Compensation Program). The number of stock options or SARs awarded to each employee will be
determined on grant date by determining the USD value of the award chosen by the employee to be paid in stock options and dividing that
value by the grant date GAAP expense of one stock option. The result will be rounded up to the nearest whole share. Any STAR award paid
in stock options or other form of equity shall be awarded pursuant to this program and the terms and conditions of the 2014 Plan or any
successor stock plan approved in accordance with applicable listing standards, as they may be revised from time to time. STAR awards paid
in stock options or SARS will have the following terms unless otherwise approved by the C&LD Committee at grant:
Grant date will be the last business day on or before September 15. If the New York Stock Exchange is closed on the day of the grant, then
the C&LD Committee will establish a grant date as soon as practical following the date previously specified. Provided participants remain in
compliance with the terms and conditions set forth in the currently active Stock Plan and the Regulations, STAR stock options and SARs are
not forfeitable, will become exercisable three years after the grant date, and will expire ten years after the grant date. In the event of death of
the participant, the award becomes exercisable as of the date of death and the award remains exercisable until the Expiration Date. For awards
granted in France or the United Kingdom, the consequences of death are determined by the local plan supplement, if applicable.
The option price used for any STAR Award will be the closing price for a share of Common Stock on the New York Stock Exchange on the
grant date, or such higher price as may be specified in the French Addendum of the Regulations (the “Grant Price”).

-- 35 of 45 --

IV. 	SEPARATION FROM THE COMPANY
• 	Retirement, Death or Special Separation with a Separation Package: If a participant worked at least 28 days (4 calendar weeks)
during the fiscal year, the STAR award is pro-rated by dividing the number of calendar days the participant was an “active employee”
during the fiscal year by 365.
• 	Voluntary Resignation or Termination for cause: 	Separating employees must have been active employees as of June 30 or the last
business day in June (the close of the fiscal year for which the award is payable) to receive an award.
• 	Separation due to a Company authorized divestiture: 	In the case of divestitures the CHRO is authorized to determine the appropriate
STAR payout based on Business Unit factors either at Target or at projected or actual business results. The CHRO is also authorized to
pay awards for the current or following partial fiscal year at time of divestiture close for administrative convenience.
Eligible participants who have left the Company will receive a cash payment (stock options can only be issued to active employees) 	on the
same timing as STAR awards or as soon thereafter as possible.
V. 	CHANGE IN CONTROL
Notwithstanding the foregoing, if there is a Change in Control in any fiscal year, STAR awards will be calculated in accordance with Section
II above, but each factor will be calculated for the period from the beginning of the fiscal year in which a Change in Control occurred up to
and including the date of such Change in Control (“CIC Period”). “Change in Control” shall have the same meaning as defined in the 2014
Plan or any successor stock plan.
VI. 	GENERAL TERMS AND CONDITIONS
While any STAR award amount received by one individual for any year shall be considered as earned remuneration in addition to salary paid,
it shall be understood that this plan does not give to any officer or employee any contract rights, express or implied, against any Company for
any STAR award or for compensation in addition to the salary paid to him or her, or any right to question the action of the Board of Directors
or the C&LD or STAR Committees.
The Chief Human Resources Officer or the Chief Legal Officer may withhold a STAR award for a separated employee who is discovered to
have engaged in serious misconduct or actions detrimental to the Company’s interests.
Each award to an individual at Band 7 and above, made pursuant to this plan, is subject to the Senior Executive Recoupment Policy as
amended by the C&LD Committee in April 2018.
To the extent applicable, it is intended that STAR comply with the provisions of Section 409A. STAR will be administered and interpreted in
a manner consistent with this intent. Neither a Participant nor any of a Participant’s creditors or beneficiaries will have the right to subject any
deferred compensation (within the meaning of Section 409A) payable under STAR to any anticipation, alienation, sale, transfer, assignment,
pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A, any deferred compensation (within the meaning
of Section 409A) payable to a Participant under STAR may not be reduced by, or offset against, any amount owing by a Participant to the
Company.
This program document may be amended at any time by the C&LD Committee.

-- 36 of 45 --

Exhibit (10-2)
The Procter & Gamble Performance Stock Program Summary

-- 37 of 45 --

PERFORMANCE STOCK PROGRAM SUMMARY
(Effective July 1, 2019)
The Performance Stock Program (“PSP”) is a part of The Procter & Gamble Company’s (the “Company”) long-term incentive (“LTI”)
compensation and is designed to provide additional focus on key Company measures for top executives with senior management
responsibility for total Company results. Awards granted under the PSP (“PSP Awards”) are made pursuant to authority delegated to the
Compensation & Leadership Development Committee (the “C&LD Committee”) by the Board of Directors for determining compensation for
the Company’s principal officers and for making awards under the Procter & Gamble 2014 Stock and Incentive Compensation Plan (the
“2014 Plan”) or any successor stock plan approved in accordance with applicable listing standards. PSP Awards are Performance-Based
Compensation (as defined in Article 15 of the 2014 Plan).
I. 	ELIGIBILITY
The Chairman of the Board and/or Chief Executive Officer and those active executives at Band 6 or above as of October 1 prior to the grant
date and recommended by management are eligible to participate (“Participants”). In special circumstances such as for acquisitions or
experienced hires, the CHRO may authorize participation for Band 6 or above employees who are not active as of October 1 but are active
employees as of the grant date.
II. 	OVERVIEW
A significant portion of the Band 6 and above compensation is delivered through two long-term incentive programs tied to Company
performance: PSP and the Long-term Incentive Program.
Total long-term incentive compensation targets are based on relevant competitive market data considering the median total long-term
compensation of comparable positions, regressed for revenue size. The C&LD Committee establishes the Peer Group and sets compensation
targets for all Principal Officers including the CEO. The CEO approves compensation targets for non-Principal Officers (generally Band 6
managers).
The C&LD Committee determines the long-term incentive award for the CEO. The CEO recommends all other Principal Officer awards to
the C&LD Committee based on benchmarked long-term compensation targets, adjusted for business results and individual contributions
attributable to each executive and including that individual’s leadership skills. The C&LD Committee retains full authority to accept, modify,
or reject these recommendations. The CEO approves awards for participants who are not Principal Officers based on long-term compensation
targets, business results and individual contributions. Long-term incentive awards can be up to 50% above or 50% below the benchmarked
target. In exceptional cases, no award will be made. After total LTI award size is determined then approximately half of each Band 7
manager’s long-term compensation is allocated to PSP via an Initial PSU Grant (as defined below). The remaining portion is a Long-term
Incentive Program Grant. Approximately 25% of each Band 6 manager’s total LTI is allocated to PSP with the remainder awarded under the
Long-term Incentive Program.
PSP rewards Participants for Company performance against certain three-year performance goals in categories established by the C&LD
Committee. The C&LD Committee sets these performance goals for each three-year period that begins on July 1 and ends on June 30 three
years later (“Performance Period”). In the first year of each Performance Period, the C&LD Committee grants Performance Stock Units
(“PSUs”) to Participants that will vest at the end of the Performance Period based on the Company’s performance relative to the pre-
established performance goals (“Initial PSU Grant”). The number of PSUs that vest at the end of the Performance Period depends on the
Company’s performance against the pre-established performance goals. Vested PSUs, including dividend equivalents, are converted into
shares of the Company’s common stock (“Common Stock”) delivered to the applicable Participant within 60 days following the end of the
Performance Period, or such later date as may be elected by the Participant in accordance with Section 409A of the Internal Revenue Code
(“Section 409A”).

-- 38 of 45 --

III. 	PERFORMANCE CATEGORIES
The PSP Award is based on the Company’s performance in each of the following categories (each a “Performance Category”) and weighted
as indicated:
· 	Organic sales growth (percentile rank in the competitive peer group)* - 30%
· 	Constant currency core before-tax operating profit growth - 20%
· 	Core earnings per share (EPS) growth - 30%
· 	Adjusted free cash flow productivity - 20%
Awards will be further adjusted based on the three-year relative total shareholder return (R-TSR) of P&G compared to the competitive peer
group*. Awards will be adjusted for top quartile performance using a 125% multiplier to increase awards, and reduced for bottom quartile
performance using a 75% multiplier.
* 	Competitive peer group is defined in the PSP Accounting Guidelines.
Within the first 90 days of each Performance Period, the C&LD Committee sets three-year performance goals (“Performance Goals”) for
each Performance Category for such Performance Period and establishes a sliding scale to measure the Company’s performance against each
Performance Goal in each Performance Category. The C&LD Committee uses the sliding scale to establish a payout factor between 0% and
200% for each Performance Category (a “Sales Factor”, “Profit Factor”, “EPS Factor” and “Cash Flow Factor”, collectively, “Performance
Factors”).
In all cases, the C&LD Committee retains the discretion to include or exclude certain of the Performance Categories for purposes of
determining the PSP Award. The C&LD Committee may reduce or eliminate any payment if it determines that such payout is inconsistent
with long-term shareholders’ interests 	or incongruous with the overall performance of the company.
PSP awards will have the following terms unless otherwise approved by the C&LD Committee:
IV. 	THE INITIAL PSU GRANT
The C&LD Committee has the sole discretion to establish the target award (“PSP Target”) for each Participant serving as a Principal Officer.
The CEO establishes the PSP Targets for participants who are not Principal Officers. The PSP Target will be a cash amount and will be the
basis for the Initial PSU Grant. The C&LD Committee will make the Initial PSU Grant on the last business date in February (“Grant Date”)
following the beginning of each Performance Period. If the New York Stock Exchange is closed on the day of the grant, then the C&LD will
establish a grant date as soon as practical subsequent to the date previously specified for such award. The Initial PSU Grant will set forth a
target and maximum number of PSUs. The target number of PSUs will be determined by dividing the PSP Target by the expense value of one
PSU using the same methodology by which the Company expenses PSUs, rounding to the nearest whole unit.
The Initial PSU Grant maximum will be two times the Initial PSU Grant.
V. 	PSU VESTING AND PAYMENT
After the Performance Period is complete, the C&LD Committee will establish the Payout Factors for each of the Performance Categories
based on the Company’s results versus the pre-established Performance Goals. The number of PSUs that vest will be determined by
multiplying the Performance Factors by their respective weightings, summing up the results, then applying the R-TSR multiplier if
applicable. The final result will be rounded up or down to the nearest full percentage. The resulting percentage will be applied to the number
of PSUs in the Initial PSU Grant target, including dividends that would have accumulated since the initial PSU grant on the vested units. Any
resulting fractional share units may be paid as cash, fractional shares, or rounded up to the next full share based on administrative preference
of the Company. The number of PSUs that vest may be equal to, above or below the Initial PSU Grant target depending on the Company’s
performance in the Performance

-- 39 of 45 --

Categories, but in no event more than the Initial PSU Grant maximum. Vested PSUs are converted into shares of Common Stock delivered to
the applicable Participant within 60 days following the end of the Performance Period, or such later date as may be elected by the Participant
if applicable and in accordance with Section 409A.
Participants at Band 7 and above may elect to defer delivery of the Common Stock by electing to receive Restricted Stock Units. PSP RSUs
will have the following terms unless otherwise approved by the Committee at grant:
VESTING AND SETTLEMENT: PSP RSUs will be vested on the grant date with a settlement date at least one year following the
original PSU delivery date (as elected by the Participant), are eligible for dividend equivalents, and can be further deferred in accordance
with Section 409A. These RSUs will be paid on their Original Settlement Date or the Agreed Settlement Date, except in the case of death.
In the case of death (except in France and the UK), payment will be made by the later of the end of the calendar year or two and a half
months following the date of death. For awards granted in France or the UK, the consequences of death are determined by the local plan
supplement, if applicable.
VI. 	SEPARATION FROM THE COMPANY 	(Defined terms shall have the meaning designated in the 2014 Plan or related award
documents)
If the Participant’s Termination of Employment occurs for any reason before the Vest Date, except for the reasons listed below, the Award
will be forfeited. Participants must remain in compliance with the terms and conditions set forth in the 2014 Plan, including those in Article 6.
• 	Termination on Account of Death (except in France and the UK). 	The Award is immediately vested and will become deliverable
on the Settlement Date or Agreed Settlement Date, whichever is applicable.
• 	Termination on Account of Death for awards granted in France or the UK. 	The consequences of death are determined by the local
plan supplement, if applicable.
• 	Termination on Account of Retirement or Disability after June 30th of the fiscal year in which this Award was granted. 	PSUs are
retained and will be delivered on the Settlement Date.
• 	Termination pursuant to a Written Separation Agreement that provides for retention of the Award, after June 30th of the fiscal
year in which this Award was granted. 	PSUs are retained and will be delivered on the Settlement Date.
• 	Termination in connection with a divestiture or separation of any of the Company’s businesses, as determined by the Company’s
Chief Human Resources Officer. 	PSUs are retained and will be delivered on the Settlement Date.
VII. 	CHANGE IN CONTROL
Notwithstanding the foregoing, if there is a Change in Control that meets the requirements of a change in control event under Section 409A,
all outstanding PSP Awards will vest at 100% of the Initial PSU Grant target (or 100% of the PSP Target if the Change in Control occurs
prior to the Initial PSU Grant) including dividends that would have accumulated since the initial PSU grant on the vested units, and shall be
paid in shares of Common Stock at the time of such Change in Control. If there is a Change in Control event that does not meet the
requirements of a change in control event under Section 409A, all outstanding PSP Awards will be settled according to the terms and
conditions set forth herein, without the application Article 17 of the 2014 Plan. “Change in Control” shall have the same meaning as defined
in the 2014 Plan or any successor stock plan approved in accordance with applicable listing standards.

-- 40 of 45 --

VIII. 	GENERAL TERMS AND CONDITIONS
It shall be understood that the PSP does not give to any officer or employee any contract rights, express or implied, against any Company for
any PSP Award, or for compensation in addition to the salary paid to him or her, or any right to question the action of the Board of Directors
or the C&LD Committee.
Each PSP Award made to an individual at Band 7 and above is subject to the Senior Executive Recoupment Policy adopted by the C&LD
Committee in December 2006.
To the extent applicable, it is intended that the PSP comply with the provisions of Section 409A. The PSP will be administered and
interpreted in a manner consistent with this intent. Neither a Participant nor any of a Participant’s creditors or beneficiaries will have the right
to subject any deferred compensation (within the meaning of Section 409A) payable under the PSP to any anticipation, alienation, sale,
transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted under Section 409A, any deferred compensation
(within the meaning of Section 409A) payable to a Participant under the PSP may not be reduced by, or offset against, any amount owing by
a Participant to the Company.
This program document may be amended at any time by the C&LD Committee

-- 41 of 45 --

EXHIBIT 31.1
Rule 13a-14(a)/15d-14(a) Certifications
I, David S. Taylor, certify that:
(1) 	I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3) 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) 	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) 	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
/s/ DAVID S. TAYLOR
(David S. Taylor)
Chairman of the Board, President and Chief Executive Officer
October 22, 2019
Date

-- 42 of 45 --

EXHIBIT 31.2
Rule 13a-14(a)/15d-14(a) Certifications
I, Jon R. Moeller, certify that:
(1) 	I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
(3) 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) 	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) 	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
/s/ JON R. MOELLER
(Jon R. Moeller)
Vice Chairman and Chief Financial Officer
October 22, 2019
Date

-- 43 of 45 --

EXHIBIT 32.1
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) 	The Quarterly Report on Form 10-Q of the Company for the quarterly period ended 	September 30, 2019 	fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.
/s/ DAVID S. TAYLOR
(David S. Taylor)
Chairman of the Board, President and Chief Executive Officer
October 22, 2019
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter &
Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 44 of 45 --

EXHIBIT 32.2
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) 	The Quarterly Report on Form 10-Q of the Company for the quarterly period ended 	September 30, 2019 	fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the Company.
/s/ JON R. MOELLER
(Jon R. Moeller)
Vice Chairman and Chief Financial Officer
October 22, 2019
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter &
Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 45 of 45 --